<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="//www.biomarin.com/wp-content/plugins/wordpress-seo/css/main-sitemap.xsl"?>
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-image/1.1 http://www.google.com/schemas/sitemap-image/1.1/sitemap-image.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-demonstrates-normalization-of-carbohydrate-storage-in-brain-tissue-using-an-mps-i-model/</loc>
		<lastmod>2003-09-03T13:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-halts-phase-3a-study-of-neutralase-in-cabg-and-terminates-the-neutralase-drug-development-program/</loc>
		<lastmod>2003-09-21T13:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2003-financial-results/</loc>
		<lastmod>2003-11-03T13:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-positive-long-term-results-from-ongoing-phase-1-and-phase-2-clinical-studies-of-aryplase-for-mps-vi/</loc>
		<lastmod>2003-11-05T13:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-accelerates-development-of-phenoptin-a-novel-oral-enzyme-cofactor-for-the-treatment-of-pku/</loc>
		<lastmod>2003-11-19T13:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/pnas-study-from-biomarin-highlights-possible-new-approach-for-improving-the-efficacy-of-enzyme-and-protein-replacement-therapies/</loc>
		<lastmod>2003-12-29T13:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-obtain-profitable-pediatric-business-from-medicis/</loc>
		<lastmod>2004-04-20T13:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2004-financial-results/</loc>
		<lastmod>2004-05-03T13:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-ascent-pediatrics-transaction/</loc>
		<lastmod>2004-05-18T13:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-phase-3-data-on-aryplasetm-for-mps-vi/</loc>
		<lastmod>2004-06-02T13:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-from-clinical-study-of-6r-bh4-in-pku-patients/</loc>
		<lastmod>2004-07-19T13:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2004-financial-results/</loc>
		<lastmod>2004-08-09T13:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-resignation-of-chairman-and-ceo-and-plans-for-succession/</loc>
		<lastmod>2004-08-12T13:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-files-investigational-new-drug-application-for-phenoptin-6r-bh4-for-the-treatment-of-pku/</loc>
		<lastmod>2004-08-23T13:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-data-from-phase-1b-clinical-trial-of-vibrilase-for-serious-burns/</loc>
		<lastmod>2004-08-24T13:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-annual-biomarin-mps-run-for-your-life-5k-run-walk/</loc>
		<lastmod>2004-09-21T13:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2004-financial-results/</loc>
		<lastmod>2004-11-02T13:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-forms-strategic-partnership-with-daiichi-suntory-pharma-for-phenoptin-to-treat-phenylketonuria/</loc>
		<lastmod>2004-11-22T13:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-u-s-biologics-license-application-for-marketing-authorization-of-aryplase-for-mps-vi/</loc>
		<lastmod>2004-11-28T13:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-initiate-a-phase-3-clinical-trial-of-phenoptin-in-pku-in-the-first-quarter-of-2005/</loc>
		<lastmod>2004-11-29T13:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-marketing-authorization-application-in-european-union-for-aryplase-to-treat-mps-vi/</loc>
		<lastmod>2004-12-05T13:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-enrolls-first-patient-into-phase-2-clinical-trial-of-phenoptin-for-pku/</loc>
		<lastmod>2004-12-22T13:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-year-end-2004-product-revenues-and-2005-product-revenue-guidance/</loc>
		<lastmod>2005-01-25T13:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-accepts-and-grants-six-month-review-for-biomarins-marketing-application-for-rhasb-for-mps-vi/</loc>
		<lastmod>2005-01-31T13:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-year-end-2004-financial-results/</loc>
		<lastmod>2005-02-22T13:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-phase-3-extension-study-of-rhasb-in-mps-vi-demonstrates-additional-improvements-in-endurance/</loc>
		<lastmod>2005-03-08T13:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-3-clinical-trial-of-phenoptin-for-pku/</loc>
		<lastmod>2005-04-06T13:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-acquires-rights-to-6r-bh4-for-treating-vascular-dysfunction-in-diabetes-and-cardiovascular-disease/</loc>
		<lastmod>2005-05-04T13:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2005-financial-results/</loc>
		<lastmod>2005-05-05T13:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-appointment-of-jean-jacques-bienaime-as-chief-executive-officer/</loc>
		<lastmod>2005-05-11T13:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-serono-form-strategic-alliance-for-the-development-and-commercialization-of-phenoptintm-and-phenylasetm/</loc>
		<lastmod>2005-05-15T13:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-hold-conference-call-today-may-16-at-1200-pm-edt-1800-cest-to-discuss-recent-company-developments-and-first-quarter-2005-financial-results/</loc>
		<lastmod>2005-05-16T13:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-approval-for-naglazyme/</loc>
		<lastmod>2005-05-31T13:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-webcast-presentation-at-the-morgan-stanely-small-cap-executive-conference/</loc>
		<lastmod>2005-06-13T13:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-u-s-launch-of-naglazyme-for-mps-vi/</loc>
		<lastmod>2005-06-21T13:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-reduction-of-orapred-sales-force/</loc>
		<lastmod>2005-07-05T13:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-public-offering-of-8500000-shares-of-common-stock/</loc>
		<lastmod>2005-07-14T13:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-files-new-drug-application-for-orapred-odt/</loc>
		<lastmod>2005-08-01T13:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-new-chief-financial-officer/</loc>
		<lastmod>2005-08-23T13:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-newsmakers-in-the-biotech-industry-conference/</loc>
		<lastmod>2005-09-07T13:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-opinion-for-naglazyme-from-european-regulatory-authority/</loc>
		<lastmod>2005-09-15T13:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-2005-ubs-global-life-science-conference/</loc>
		<lastmod>2005-09-20T13:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bio-investor-forum-conference/</loc>
		<lastmod>2005-10-13T13:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-u-s-fda-acceptance-of-orapred-odt-filing/</loc>
		<lastmod>2005-10-19T13:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-rodman-and-renshaw-techvest-7th-annual-healthcare-conference/</loc>
		<lastmod>2005-10-31T13:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2005-financial-results/</loc>
		<lastmod>2005-11-01T13:20:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-named-marin-countys-business-of-the-year/</loc>
		<lastmod>2005-11-14T13:20:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-research-and-development-day-on-tuesday-december-6/</loc>
		<lastmod>2005-11-22T12:54:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-establishes-commercial-operations-in-europe/</loc>
		<lastmod>2006-01-10T12:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-fda-fast-track-designation-for-phenoptin-for-pku/</loc>
		<lastmod>2006-01-25T12:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-marketing-approval-for-naglazyme-in-european-union/</loc>
		<lastmod>2006-01-30T12:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-year-end-2005-financial-results/</loc>
		<lastmod>2006-02-23T12:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-cowen-co-26th-annual-health-care-conference/</loc>
		<lastmod>2006-02-27T12:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-serono-announce-positive-results-from-phase-3-clinical-study-of-phenoptin-for-pku/</loc>
		<lastmod>2006-03-15T12:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-proposed-concurrent-public-offerings-of-common-stock-and-senior-subordinated-convertible-notes/</loc>
		<lastmod>2006-03-20T12:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-closing-of-295-million-concurrent-public-offerings-of-common-stock-and-senior-subordinated-convertible-notes-2/</loc>
		<lastmod>2006-03-23T12:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-closing-of-295-million-concurrent-public-offerings-of-common-stock-and-senior-subordinated-convertible-notes/</loc>
		<lastmod>2006-03-30T12:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-leerink-swann-company-medacorp-hypertension-roundtable-conference/</loc>
		<lastmod>2006-04-20T12:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2006-financial-results/</loc>
		<lastmod>2006-05-03T12:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-rodman-and-renshaw-3rd-annual-global-healthcare-conference/</loc>
		<lastmod>2006-05-08T12:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bear-biotech-boston-confab/</loc>
		<lastmod>2006-05-24T12:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-alliant-announce-fda-approval-of-orapred-odt/</loc>
		<lastmod>2006-06-01T11:59:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-2006-pacific-growth-equities-life-sciences-growth-conference/</loc>
		<lastmod>2006-06-05T11:57:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-2-clinical-study-of-6r-bh4-in-poorly-controlled-hypertension/</loc>
		<lastmod>2006-07-06T11:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2006-financial-results/</loc>
		<lastmod>2006-08-02T11:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-u-s-launch-of-orapred-odt-through-alliant-pharmaceuticals/</loc>
		<lastmod>2006-08-28T11:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-thomas-weisel-partners-healthcare-conference-2006/</loc>
		<lastmod>2006-08-30T11:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-biocenturys-newsmakers-in-the-biotech-industry-conference/</loc>
		<lastmod>2006-08-31T11:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-update-on-phenylase-product-development/</loc>
		<lastmod>2006-09-11T11:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-serono-announce-data-on-phenoptin-in-pku-to-be-presented-at-the-56th-annual-meeting-of-the-american-society-of-human-genetics/</loc>
		<lastmod>2006-09-12T11:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-enrollment-of-phase-2-clinical-study-of-6r-bh4-in-poorly-controlled-hypertension/</loc>
		<lastmod>2006-09-20T11:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-partial-exchange-of-convertible-notes-due-2008-for-common-stock/</loc>
		<lastmod>2006-09-25T11:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-rodman-and-renshaw-8th-annual-healthcare-conference/</loc>
		<lastmod>2006-10-31T11:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2006-financial-results/</loc>
		<lastmod>2006-11-01T11:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-cowen-and-company-7th-annual-global-healthcare-conference/</loc>
		<lastmod>2006-11-02T11:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-from-phase-3-extension-study-of-phenoptin-for-pku/</loc>
		<lastmod>2006-12-18T11:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-calls-remaining-51-4-million-of-convertible-notes-due-2008/</loc>
		<lastmod>2006-12-22T11:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-2-clinical-study-of-6r-bh4-in-peripheral-arterial-disease/</loc>
		<lastmod>2007-01-04T11:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-jpmorgan-25th-annual-healthcare-conference/</loc>
		<lastmod>2007-01-07T11:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-from-phase-3-diet-study-of-phenoptin-for-pku/</loc>
		<lastmod>2007-01-16T11:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/remaining-51-4-million-of-convertible-notes-due-2008-converted-into-common-stock/</loc>
		<lastmod>2007-01-29T11:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-merrill-lynch-global-pharmaceutical-biotechnology-medical-device-conference/</loc>
		<lastmod>2007-01-31T11:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2006-financial-results-conference-call-and-webcast-on-thursday-february-22-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2007-02-15T11:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-date-and-time-change-of-fourth-quarter-and-full-year-2006-financial-results-conference-call-and-webcast-to-tuesday-february-20-at-1100-a-m-et-1700-cet/</loc>
		<lastmod>2007-02-16T11:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2006-financial-results/</loc>
		<lastmod>2007-02-20T11:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-cowen-and-company-27th-annual-health-care-conference/</loc>
		<lastmod>2007-03-06T11:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-lehman-brothers-tenth-annual-global-healthcare-conference/</loc>
		<lastmod>2007-03-12T11:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-proposed-offering-of-250-million-senior-subordinated-convertible-notes/</loc>
		<lastmod>2007-04-16T11:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-public-offering-of-282-5-million-senior-subordinated-convertible-notes/</loc>
		<lastmod>2007-04-18T11:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2007-financial-results-conference-call-and-webcast-on-wednesday-may-2-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2007-04-19T11:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-closing-of-324875000-public-offering-of-senior-subordinated-convertible-notes/</loc>
		<lastmod>2007-04-23T11:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2007-financial-results/</loc>
		<lastmod>2007-04-30T11:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-2a-clinical-study-of-6r-bh4-in-sickle-cell-disease/</loc>
		<lastmod>2007-05-02T11:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-rodman-renshaw-4th-annual-global-healthcare-conference/</loc>
		<lastmod>2007-05-07T11:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-citigroup-global-healthcare-conference/</loc>
		<lastmod>2007-05-16T11:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-new-drug-application-for-u-s-marketing-authorization-of-kuvan-for-phenylketonuria-pku/</loc>
		<lastmod>2007-05-24T11:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bank-of-america-health-care-conference/</loc>
		<lastmod>2007-05-29T11:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-nasdaq-19th-investor-program/</loc>
		<lastmod>2007-06-12T11:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-expanded-access-program-for-kuvan-in-the-u-s/</loc>
		<lastmod>2007-06-18T11:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2007-financial-results-conference-call-and-webcast-on-tuesday-august-7-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2007-07-24T11:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/kuvan-receives-priority-review-status-from-fda/</loc>
		<lastmod>2007-07-25T11:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2007-financial-results/</loc>
		<lastmod>2007-08-07T11:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/positive-kuvantm-pivotal-phase-3-trial-results-published-in-the-lancet/</loc>
		<lastmod>2007-08-13T11:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-licenses-technology-from-leading-cystic-fibrosis-research-laboratory-at-the-university-of-california-san-francisco/</loc>
		<lastmod>2007-08-22T11:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-biocentury-newsmakers-conference/</loc>
		<lastmod>2007-08-30T11:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bear-stearns-20th-annual-healthcare-conference/</loc>
		<lastmod>2007-09-04T11:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/exclusive-rights-to-kuvantm-data-licensed-to-asubio-pharma-in-japan/</loc>
		<lastmod>2007-09-17T11:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/meta-analysis-of-blood-phe-levels-and-clinical-outcomes-in-pku-published/</loc>
		<lastmod>2007-09-27T11:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/kuvan-naglazyme-and-aldurazyme-data-to-be-presented-at-the-57th-annual-meeting-of-the-american-society-of-human-genetics/</loc>
		<lastmod>2007-10-17T11:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2007-financial-results-conference-call-and-webcast-on-thursday-november-1-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2007-10-18T11:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-grant-to-nord-to-expand-pku-patient-support-services/</loc>
		<lastmod>2007-10-24T11:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-rodman-renshaw-9th-annual-healthcare-conference/</loc>
		<lastmod>2007-10-31T10:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2007-financial-results/</loc>
		<lastmod>2007-11-01T10:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-credit-suisse-healthcare-conference-3/</loc>
		<lastmod>2007-11-06T10:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/maa-submitted-to-emea-for-european-marketing-authorization-of-sapropterin-for-hyperphenylalaninemia-hpa/</loc>
		<lastmod>2007-11-08T10:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-files-investigational-new-drug-application-for-peg-pal-for-the-treatment-of-pku/</loc>
		<lastmod>2007-11-27T10:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-igan-biosciences-to-collaborate-on-development-of-an-enzyme-therapy-to-treat-iga-nephropathy-a-rare-and-life-threatening-kidney-disease/</loc>
		<lastmod>2007-12-03T10:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-approval-for-kuvan/</loc>
		<lastmod>2007-12-13T10:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-re-acquires-rights-to-kuvan-in-canada-from-merck-serono/</loc>
		<lastmod>2007-12-18T10:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-genzyme-restructure-aldurazyme-50-50-joint-venture/</loc>
		<lastmod>2008-01-03T10:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/steve-glass-appointed-vice-president-and-general-manager-biomarin-europe-ltd/</loc>
		<lastmod>2008-01-22T10:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-wachovia-2008-healthcare-conference/</loc>
		<lastmod>2008-01-23T10:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-dr-gordon-vehar-vice-president-of-research/</loc>
		<lastmod>2008-01-28T10:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-merrill-lynch-2008-global-healthcare-conference/</loc>
		<lastmod>2008-01-30T10:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2007-financial-results-conference-call-and-webcast-on-tuesday-february-26-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2008-02-05T10:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2007-financial-results/</loc>
		<lastmod>2008-02-26T10:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-cowen-and-company-28th-annual-healthcare-conference/</loc>
		<lastmod>2008-03-11T10:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-lehman-brothers-global-healthcare-conference/</loc>
		<lastmod>2008-03-12T10:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/naglazyme-approved-by-japanese-ministry-of-health/</loc>
		<lastmod>2008-03-31T10:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2008-financial-results-conference-call-and-webcast-on-tuesday-april-29-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2008-04-08T10:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-morgan-stanley-healthcare-conference-2/</loc>
		<lastmod>2008-04-24T10:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2008-financial-results/</loc>
		<lastmod>2008-04-29T10:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-baird-growth-stock-conference-3/</loc>
		<lastmod>2008-05-06T10:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bank-of-america-healthcare-conference/</loc>
		<lastmod>2008-05-07T10:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-clinical-study-of-peg-pal-in-pku/</loc>
		<lastmod>2008-05-20T10:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-research-and-development-day-june-5th/</loc>
		<lastmod>2008-05-22T10:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-program-for-ert-for-treatment-of-mps-iva-morquio-a-syndrome/</loc>
		<lastmod>2008-06-05T10:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-collins-stewart-growth-conference/</loc>
		<lastmod>2008-07-01T10:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2008-financial-results-conference-call-and-webcast-on-tuesday-august-5-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2008-07-15T10:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biopten-sapropterin-dihydrochloride-approved-by-japanese-ministry-of-health-for-the-treatment-of-pku/</loc>
		<lastmod>2008-07-16T10:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-summit-plc-sign-worldwide-licensing-agreement-for-duchenne-muscular-dystrophy-program/</loc>
		<lastmod>2008-07-22T10:20:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2008-financial-results/</loc>
		<lastmod>2008-08-05T10:20:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-roll-out-of-national-pku-registry/</loc>
		<lastmod>2008-08-21T10:19:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-morgan-stanley-global-healthcare-conference/</loc>
		<lastmod>2008-09-02T10:19:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-merrill-lynch-global-pharmaceutical-conference/</loc>
		<lastmod>2008-09-11T10:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-corrects-information-included-in-bloomberg-article/</loc>
		<lastmod>2008-09-18T10:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/kuvan-receives-positive-opinion-from-chmp-for-european-approval/</loc>
		<lastmod>2008-09-25T10:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-opens-office-in-brisbane-to-support-expanding-operations/</loc>
		<lastmod>2008-10-07T10:13:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-from-phase-2a-clinical-study-of-6r-bh4-in-sickle-cell-disease/</loc>
		<lastmod>2008-10-15T10:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2008-financial-results/</loc>
		<lastmod>2008-10-28T10:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-initiation-of-clinical-assessment-program-for-morquio-a-syndrome/</loc>
		<lastmod>2008-11-03T10:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-credit-suisse-healthcare-conference-2/</loc>
		<lastmod>2008-11-05T10:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/data-to-be-presented-at-58th-annual-meeting-of-the-american-society-of-human-genetics/</loc>
		<lastmod>2008-11-06T10:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-the-planned-retirement-of-dr-emil-kakkis-chief-medical-officer/</loc>
		<lastmod>2008-11-21T10:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-piper-jaffray-healthcare-conference/</loc>
		<lastmod>2008-11-25T10:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/kuvan-receives-marketing-approval-in-the-european-union/</loc>
		<lastmod>2008-12-09T10:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-la-jolla-pharmaceutical-sign-worldwide-excluding-asia-pacific-development-and-commercialization-agreement-for-riquent/</loc>
		<lastmod>2009-01-06T13:57:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-27th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2009-01-07T13:56:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2008-financial-results-conference-call-and-webcast-on-wednesday-february-18-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2009-01-28T13:56:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/results-from-phase-2-clinical-study-of-6r-bh4-in-peripheral-arterial-disease-not-statistically-significant/</loc>
		<lastmod>2009-02-03T13:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/results-of-first-interim-efficacy-analysis-for-riquent-phase-3-aspen-trial-continuation-of-the-trial-is-futile/</loc>
		<lastmod>2009-02-12T13:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2008-financial-results/</loc>
		<lastmod>2009-02-18T13:54:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-supports-observance-of-rare-disease-day-february-28-2/</loc>
		<lastmod>2009-02-26T13:54:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-dr-henry-j-fuchs-as-senior-vice-president-and-chief-medical-officer/</loc>
		<lastmod>2009-03-02T13:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-warning-letter-to-genzyme-related-to-the-allston-manufacturing-facility/</loc>
		<lastmod>2009-03-03T13:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-barclays-capital-global-healthcare-conference-2/</loc>
		<lastmod>2009-03-04T13:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-cowen-and-company-29th-annual-health-care-conference/</loc>
		<lastmod>2009-03-10T13:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-clinical-trial-application-for-galns-for-morquio-a-syndrome-accepted-by-the-mhra/</loc>
		<lastmod>2009-03-18T13:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-4th-annual-citi-biotech-day/</loc>
		<lastmod>2009-03-25T13:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-notice-of-allowance-for-once-daily-dosing-patent-for-kuvan/</loc>
		<lastmod>2009-03-30T13:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2009-financial-results-conference-call-and-webcast-on-thursday-april-30-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2009-04-09T13:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-2-clinical-trial-for-galns-for-morquio-a-syndrome/</loc>
		<lastmod>2009-04-21T13:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2009-financial-results/</loc>
		<lastmod>2009-04-30T13:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-baird-growth-stock-conference-2/</loc>
		<lastmod>2009-05-07T13:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-deutsche-bank-health-care-conference/</loc>
		<lastmod>2009-05-12T13:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-2009-corporate-award-for-the-development-of-kuvan/</loc>
		<lastmod>2009-05-15T13:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-goldman-sachs-healthcare-conference-2/</loc>
		<lastmod>2009-06-02T13:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-william-blair-growth-stock-conference-2/</loc>
		<lastmod>2009-06-03T13:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/results-from-phase-1-clinical-study-of-peg-pal-in-pku-and-update-on-phase-2-clinical-study/</loc>
		<lastmod>2009-06-09T13:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/kuvan-receives-priority-review-status-from-health-canada/</loc>
		<lastmod>2009-06-10T13:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/temporary-production-interruption-at-allston-landing-manufacturing-facility-has-no-impact-on-aldurazyme/</loc>
		<lastmod>2009-06-16T13:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2009-financial-results-conference-call-and-webcast-on-thursday-july-30-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2009-07-01T13:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/patient-enrollment-complete-for-phase-i-ii-clinical-trial-for-galns-for-morquio-a-syndrome/</loc>
		<lastmod>2009-07-13T13:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2009-financial-results/</loc>
		<lastmod>2009-07-30T13:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/kuvan-and-naglazyme-data-to-be-presented-at-the-11th-annual-iciem-meeting/</loc>
		<lastmod>2009-08-19T13:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-thomas-weisel-partners-healthcare-conference/</loc>
		<lastmod>2009-09-02T13:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-morgan-stanley-healthcare-conference/</loc>
		<lastmod>2009-09-08T13:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-ubs-global-life-sciences-conference/</loc>
		<lastmod>2009-09-15T13:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-2-clinical-study-of-peg-pal-in-pku/</loc>
		<lastmod>2009-09-22T13:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2009-financial-results-conference-call-and-webcast-on-wednesday-october-28-at-500-p-m-et/</loc>
		<lastmod>2009-09-30T13:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/united-states-patent-office-allows-claims-covering-the-approved-administration-of-kuvan-with-food/</loc>
		<lastmod>2009-09-30T13:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-chief-executive-jean-jacques-bienaime-to-receive-most-admired-ceo-award-from-san-francisco-business-times/</loc>
		<lastmod>2009-10-09T13:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-acquires-huxley-pharmaceuticals-inc/</loc>
		<lastmod>2009-10-26T13:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-oppenheimer-healthcare-conference/</loc>
		<lastmod>2009-10-27T13:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2009-financial-results/</loc>
		<lastmod>2009-10-28T13:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-credit-suisse-healthcare-conference/</loc>
		<lastmod>2009-11-04T13:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/united-states-patent-office-issues-patent-covering-the-approved-administration-of-kuvan-with-food/</loc>
		<lastmod>2009-11-05T13:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/particles-detected-in-vials-from-genzymes-plant-not-expected-to-impact-aldurazyme-or-naglazyme/</loc>
		<lastmod>2009-11-13T13:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-nasdaq-omx-23rd-investor-program/</loc>
		<lastmod>2009-11-24T13:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-grants-orphan-drug-designation-for-34-dap-for-lems/</loc>
		<lastmod>2009-11-30T13:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/amifampridine-phosphate-receives-marketing-approval-in-the-eu-for-lems/</loc>
		<lastmod>2010-01-05T13:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-clinical-study-of-bmn-195-for-duchenne-muscular-dystrophy/</loc>
		<lastmod>2010-01-11T13:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2009-financial-results-conference-call-and-webcast-on-tuesday-february-23-at-500-p-m-et/</loc>
		<lastmod>2010-02-02T13:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-2010-guidance/</loc>
		<lastmod>2010-02-04T13:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2009-financial-results/</loc>
		<lastmod>2010-02-23T13:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-supports-observance-of-rare-disease-day-february-28/</loc>
		<lastmod>2010-02-25T13:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-cowen-and-company-30th-annual-health-care-conference/</loc>
		<lastmod>2010-03-02T13:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-barclays-capital-global-healthcare-conference/</loc>
		<lastmod>2010-03-17T13:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2010-financial-results-conference-call-and-webcast-on-thursday-april-29-at-500-p-m-et/</loc>
		<lastmod>2010-04-01T13:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-launches-firdapse-in-the-european-union/</loc>
		<lastmod>2010-04-19T13:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-deutsche-bank-healthcare-conference/</loc>
		<lastmod>2010-04-28T13:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-reports-positive-results-for-phase-i-ii-trial-for-bmn-110-for-mps-iva/</loc>
		<lastmod>2010-04-29T13:14:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2010-financial-results/</loc>
		<lastmod>2010-04-29T13:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-jmp-securities-research-conference/</loc>
		<lastmod>2010-05-04T13:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-baird-growth-stock-conference/</loc>
		<lastmod>2010-05-12T13:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-citi-global-healthcare-conference/</loc>
		<lastmod>2010-05-19T13:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-william-blair-growth-stock-conference/</loc>
		<lastmod>2010-06-08T13:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-goldman-sachs-healthcare-conference/</loc>
		<lastmod>2010-06-10T13:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-wells-fargo-healthcare-conference/</loc>
		<lastmod>2010-06-17T13:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2010-financial-results-conference-call-and-webcast-on-monday-august-2-at-500-p-m-et/</loc>
		<lastmod>2010-07-06T13:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/encouraging-preliminary-safety-and-efficacy-trends-in-phase-2-clinical-study-of-peg-pal-in-pku/</loc>
		<lastmod>2010-08-02T13:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-3b-study-to-evaluate-the-effects-of-kuvan-on-neurophychiatric-symptoms-in-subjects-with-pku/</loc>
		<lastmod>2010-08-17T12:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-orphan-drug-designation-from-the-fda-for-bmn-701-for-the-treatment-of-pompe-disease/</loc>
		<lastmod>2010-08-30T12:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/results-from-investigator-sponsored-trials-presented-at-ssiem-conference/</loc>
		<lastmod>2010-09-01T13:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-morgan-stanley-global-healthcare-conference-2/</loc>
		<lastmod>2010-09-07T13:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-robert-w-baird-healthcare-conference/</loc>
		<lastmod>2010-09-08T13:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-stifel-nicolaus-healthcare-conference/</loc>
		<lastmod>2010-09-09T13:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-ubs-global-life-sciences-conference-2/</loc>
		<lastmod>2010-09-14T13:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-a-research-and-development-day-on-october-19th-2/</loc>
		<lastmod>2010-10-05T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2010-financial-results-conference-call-and-webcast-on-thursday-october-28-at-500-p-m-et/</loc>
		<lastmod>2010-10-07T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-a-research-and-development-day-on-october-19th/</loc>
		<lastmod>2010-10-14T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-program-for-bmn-111-for-the-treatment-of-achondroplasia/</loc>
		<lastmod>2010-10-19T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2010-financial-results/</loc>
		<lastmod>2010-10-28T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-partial-exchange-of-convertible-notes-due-2013-for-common-stock/</loc>
		<lastmod>2010-11-09T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-piper-jaffray-healthcare-conference-2/</loc>
		<lastmod>2010-11-29T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/mhra-completes-review-of-cta-and-issues-notice-of-acceptance-for-bmn-673-for-genetically-defined-cancers/</loc>
		<lastmod>2010-12-02T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-deutsche-bank-2010-biofest-conference/</loc>
		<lastmod>2010-12-07T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/mhra-issues-notice-of-acceptance-for-phase-3-trial-of-galns-for-the-treatment-of-mps-iva/</loc>
		<lastmod>2010-12-14T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-j-p-morgan-29th-annual-healthcare-conference/</loc>
		<lastmod>2011-01-05T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-2-trial-for-bmn-673-for-the-treatment-of-genetically-defined-cancers/</loc>
		<lastmod>2011-01-11T11:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-2-trial-for-bmn-701-for-the-treatment-of-pompe-disease/</loc>
		<lastmod>2011-01-19T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2010-financial-results/</loc>
		<lastmod>2011-01-24T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-pivotal-phase-3-trial-for-galns-for-the-treatment-of-mps-iva/</loc>
		<lastmod>2011-02-01T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2010-financial-results/</loc>
		<lastmod>2011-02-17T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-citi-global-healthcare-conference-2/</loc>
		<lastmod>2011-02-22T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-cowen-health-care-conference/</loc>
		<lastmod>2011-03-01T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-barclays-global-healthcare-conference/</loc>
		<lastmod>2011-03-08T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/first-of-its-kind-study-suggests-importance-of-routine-mental-health-screening-in-the-care-of-patients-suffering-from-genetic-disease-pku/</loc>
		<lastmod>2011-03-18T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2011-financial-results-conference-call-and-webcast-on-thursday-april-28-at-500-p-m-et/</loc>
		<lastmod>2011-03-28T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-deutsche-bank-healthcare-conference-2/</loc>
		<lastmod>2011-04-26T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2011-financial-results/</loc>
		<lastmod>2011-04-28T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference/</loc>
		<lastmod>2011-05-03T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-ubs-global-specialty-pharmaceuticals-conference/</loc>
		<lastmod>2011-05-18T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-jefferies-global-healthcare-conference-2/</loc>
		<lastmod>2011-05-31T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-3-trial-for-amifampridine-phosphate-for-the-treatment-of-lems/</loc>
		<lastmod>2011-06-07T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-william-blair-growth-stock-conference-3/</loc>
		<lastmod>2011-06-08T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-agrees-to-acquire-biologics-manufacturing-plant-in-ireland-from-pfizer/</loc>
		<lastmod>2011-06-23T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2011-financial-results-conference-call-and-webcast-on-thursday-july-28-at-500-p-m-et/</loc>
		<lastmod>2011-06-30T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-trial-for-bmn-673-in-patients-with-advanced-hematological-malignancies/</loc>
		<lastmod>2011-07-14T16:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-update-on-galns-phase-1-2-extension-study-mor-100/</loc>
		<lastmod>2011-07-28T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-wedbush-life-sciences-conference/</loc>
		<lastmod>2011-08-09T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-baird-health-care-conference/</loc>
		<lastmod>2011-08-30T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-morgan-stanley-global-healthcare-conference-3/</loc>
		<lastmod>2011-09-07T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-ubs-global-life-sciences-conference-3/</loc>
		<lastmod>2011-09-13T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-jefferies-global-healthcare-conference/</loc>
		<lastmod>2011-09-20T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2011-financial-results-conference-call-and-webcast-on-thursday-october-27-at-500-p-m-et/</loc>
		<lastmod>2011-09-29T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2011-financial-results/</loc>
		<lastmod>2011-10-27T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-credit-suisse-healthcare-conference-4/</loc>
		<lastmod>2011-11-03T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-a-research-and-development-day-on-december-8th/</loc>
		<lastmod>2011-11-17T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-approval-of-expanded-biologics-manufacturing-facility/</loc>
		<lastmod>2011-11-28T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-2-study-for-galns-in-patients-under-five-years-of-age-with-mps-iva/</loc>
		<lastmod>2011-11-29T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-buy-back-of-naglazyme-royalties-from-adelaide-health-authority/</loc>
		<lastmod>2011-11-30T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/highlights-from-biomarins-research-development-day/</loc>
		<lastmod>2011-12-08T12:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-opinion-from-european-regulatory-authorities-for-expanded-biologics-manufacturing-facility/</loc>
		<lastmod>2011-12-19T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-ind-for-bmn-111-for-achondroplasia-is-active/</loc>
		<lastmod>2012-01-03T11:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-1-trial-for-bmn-111-for-the-treatment-of-achondroplasia/</loc>
		<lastmod>2012-02-16T02:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2011-financial-results/</loc>
		<lastmod>2012-02-16T14:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-chief-financial-officer-jeffrey-cooper-to-leave-the-company/</loc>
		<lastmod>2012-02-21T14:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-enrollment-for-phase-3-trial-for-galns-for-the-treatment-of-mps-iva/</loc>
		<lastmod>2012-03-08T14:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2012-financial-results/</loc>
		<lastmod>2012-04-26T14:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-dan-spiegelman-as-executive-vice-president-and-chief-financial-officer/</loc>
		<lastmod>2012-05-08T14:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-12/</loc>
		<lastmod>2012-05-30T02:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-public-offering-of-common-stock-4/</loc>
		<lastmod>2012-05-30T14:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-public-offering-of-common-stock-4/</loc>
		<lastmod>2012-05-31T14:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11/</loc>
		<lastmod>2012-07-25T14:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2012-financial-results/</loc>
		<lastmod>2012-08-01T14:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-names-jeff-ajer-senior-vice-president-chief-commercial-officer/</loc>
		<lastmod>2012-09-05T14:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-decision-to-start-phase-3-program-for-peg-pal-in-2q-2013/</loc>
		<lastmod>2012-09-26T14:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-phase-1-results-for-bmn-111-for-achondroplasia/</loc>
		<lastmod>2012-09-26T14:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2012-financial-results/</loc>
		<lastmod>2012-10-25T14:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-phase-3-study-of-galns-for-the-treatment-of-mps-iva-meets-primary-endpoint/</loc>
		<lastmod>2012-11-05T14:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10/</loc>
		<lastmod>2012-11-19T14:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-9/</loc>
		<lastmod>2012-12-21T14:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-acquires-zacharon-pharmaceuticals/</loc>
		<lastmod>2013-01-07T14:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-8/</loc>
		<lastmod>2013-01-18T14:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/presentations-at-world-symposium-vimizim-phase-3-results-and-bmn-701-phase-1-2-patient-demographics/</loc>
		<lastmod>2013-02-11T14:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-kuvan-significantly-improves-inattentiveness-in-kuvan-responding-pku-patients/</loc>
		<lastmod>2013-02-19T14:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7/</loc>
		<lastmod>2013-02-20T14:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2012-financial-results/</loc>
		<lastmod>2013-02-21T14:41:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-licenses-factor-viii-gene-therapy-program-for-hemophilia-a-from-university-college-london-and-st-jude-childrens-research-hospital/</loc>
		<lastmod>2013-02-21T14:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-partial-exchange-of-convertible-notes-due-2017-for-common-stock/</loc>
		<lastmod>2013-03-18T14:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-advance-bmn-701-for-pompe-disease-to-next-phase-of-development/</loc>
		<lastmod>2013-03-19T14:40:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6/</loc>
		<lastmod>2013-03-19T14:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-additional-partial-exchange-of-convertible-notes-due-2017-for-common-stock/</loc>
		<lastmod>2013-03-25T14:39:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-vimizim-bla-to-the-u-s-fda-for-the-treatment-of-mps-iva/</loc>
		<lastmod>2013-04-01T14:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-cta-for-bmn-190-for-batten-disease/</loc>
		<lastmod>2013-04-01T14:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5/</loc>
		<lastmod>2013-04-18T14:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-vimizim-maa-to-ema-for-the-treatment-of-mps-iva/</loc>
		<lastmod>2013-04-24T14:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2013-financial-results/</loc>
		<lastmod>2013-04-25T14:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-bmn-673-data-in-breast-and-ovarian-cancers-to-be-released-at-asco/</loc>
		<lastmod>2013-05-16T14:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4/</loc>
		<lastmod>2013-05-20T14:37:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/vimizim-maa-validated-by-the-ema/</loc>
		<lastmod>2013-05-30T14:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-accepts-vimizim-bla-and-grants-priority-review-designation/</loc>
		<lastmod>2013-05-30T14:38:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-preliminary-data-on-ongoing-phase-1-2-trial-for-bmn-673-for-the-treatment-of-solid-tumors-at-2013-american-society-of-clinical-oncology-annual-meeting/</loc>
		<lastmod>2013-06-03T14:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-3-trial-for-peg-pal-for-the-treatment-of-pku/</loc>
		<lastmod>2013-06-05T14:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/update-jean-jacques-bienaime-ceo-of-biomarin-to-present-at-the-goldman-sachs-global-healthcare-conference/</loc>
		<lastmod>2013-06-06T14:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/vimizim-marketing-application-submitted-to-anvisa-in-brazil/</loc>
		<lastmod>2013-07-01T14:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-bmn-673-program-update/</loc>
		<lastmod>2013-07-25T14:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2013-financial-results/</loc>
		<lastmod>2013-07-25T14:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-oral-presentation-of-bmn-673-most-recent-data-on-breast-and-ovarian-cancers-at-the-european-cancer-congress-2013/</loc>
		<lastmod>2013-08-16T14:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-richard-ranieri-as-senior-vice-president-human-resources-and-corporate-affairs/</loc>
		<lastmod>2013-09-03T14:33:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-highlights-ahead-of-research-and-development-day/</loc>
		<lastmod>2013-09-17T14:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-doses-first-patient-in-phase-1-2-trial-with-bmn-190-for-the-treatment-of-neuronal-ceroid-lipofuscinosis-type-2-a-form-of-batten-disease/</loc>
		<lastmod>2013-09-23T14:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-updated-phase-1-2-data-on-bmn-673-in-breast-cancer-at-the-european-cancer-congress-2013/</loc>
		<lastmod>2013-09-29T14:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-proposed-offering-of-300-million-of-senior-subordinated-convertible-notes-due-2018-and-300-million-senior-subordinated-convertible-notes-due-2020/</loc>
		<lastmod>2013-10-07T14:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-340-million-of-senior-subordinated-convertible-notes-due-2018-and-340-million-of-senior-subordinated-convertible-notes-due-2020/</loc>
		<lastmod>2013-10-09T14:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-exercise-by-underwriters-of-full-over-allotment-option/</loc>
		<lastmod>2013-10-10T14:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/five-data-presentations-on-biomarins-bmn-673-parp-inhibitor-at-the-2013-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/</loc>
		<lastmod>2013-10-20T14:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2013-financial-results/</loc>
		<lastmod>2013-10-24T14:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-initiates-phase-3-trial-for-bmn-673-for-the-treatment-of-metastatic-gbrca-breast-cancer/</loc>
		<lastmod>2013-10-31T14:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-posts-briefing-documents-for-advisory-committee-meeting-reviewing-vimizimtm-for-the-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2013-11-15T02:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-french-atu-granted-for-vimizimtm-for-the-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2013-11-15T14:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-advisory-committee-recommends-approval-for-biomarins-vimizimtm-for-the-treatment-of-patients-with-morquio-a-syndrome/</loc>
		<lastmod>2013-11-19T02:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-stock-trading-halted-today/</loc>
		<lastmod>2013-11-19T13:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-selection-of-factor-viii-gene-therapy-drug-development-candidate-bmn-270-for-the-treatment-of-hemophilia-a/</loc>
		<lastmod>2014-01-13T13:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/american-college-of-medical-genetics-and-genomics-practice-guidelines-support-lifelong-therapy-to-manage-phenylketonuria-pku/</loc>
		<lastmod>2014-01-13T13:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-doses-first-patient-in-phase-2-trial-with-bmn-111-for-the-treatment-of-children-with-achondroplasia/</loc>
		<lastmod>2014-01-14T13:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-agreement-with-repligen-for-pre-clinical-compounds/</loc>
		<lastmod>2014-01-21T13:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-selection-of-naglu-fusion-protein-drug-development-candidate-bmn-250-for-the-treatment-of-sanfilippo-b-mps-iiib/</loc>
		<lastmod>2014-02-11T13:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-15-abstracts-from-basic-research-to-clinical-trials-at-lysosomal-disease-networks-10th-annual-worldsymposiumtm/</loc>
		<lastmod>2014-02-13T13:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-approval-for-vimizimtm-elosulfase-alfa-for-the-treatment-of-patients-with-morquio-a-syndrome/</loc>
		<lastmod>2014-02-14T13:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-discuss-fda-approval-of-vimizimtm-and-provide-preliminary-2013-results/</loc>
		<lastmod>2014-02-17T13:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-opinion-from-the-chmp-in-the-european-union-for-vimizimtm-elosulfase-alfa-for-morquio-a-syndrome/</loc>
		<lastmod>2014-02-20T13:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2013-financial-results/</loc>
		<lastmod>2014-02-26T13:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-public-offering-of-common-stock-3/</loc>
		<lastmod>2014-03-04T13:14:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-public-offering-of-common-stock-3/</loc>
		<lastmod>2014-03-05T13:13:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-pioneer-in-personalized-medicine-dennis-j-slamon-m-d-ph-d-to-board-of-directors/</loc>
		<lastmod>2014-03-22T13:13:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-extends-market-exclusivity-six-months-for-biomarins-rare-disease-therapy-kuvanr-sapropterin-dihydrochloride-powder-for-oral-solution-and-tablets/</loc>
		<lastmod>2014-04-14T13:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-european-commission-approval-for-vimizimr-elosulfase-alfa-for-the-treatment-of-morquio-a-syndrome-in-patients-of-all-ages/</loc>
		<lastmod>2014-04-28T13:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2014-financial-results-and-vimizimtm-launch-progress/</loc>
		<lastmod>2014-05-01T13:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-doses-first-patient-in-phase-3-inspire-trial-with-bmn-701-for-the-treatment-of-pompe-disease/</loc>
		<lastmod>2014-05-27T13:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-health-canada-approval-of-vimizim-elosulfase-alfa-for-the-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2014-07-07T13:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/sarah-cannon-research-institute-uk-and-biomarin-collaborate-on-embraca-clinical-study-in-hereditary-breast-cancer-with-brca-mutation/</loc>
		<lastmod>2014-07-23T13:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-sells-priority-review-voucher-for-67-5-million/</loc>
		<lastmod>2014-07-30T01:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2014-financial-results/</loc>
		<lastmod>2014-07-30T13:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-named-by-centerwatch-as-one-of-the-fastest-developers-of-medicines/</loc>
		<lastmod>2014-09-15T13:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conferences-5/</loc>
		<lastmod>2014-09-23T13:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-receives-paragraph-iv-notice-letter-for-kuvanr-sapropterin-dihydrochloride-tablets/</loc>
		<lastmod>2014-09-24T13:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2014-financial-results/</loc>
		<lastmod>2014-10-23T13:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conferences-4/</loc>
		<lastmod>2014-11-19T13:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-prosensa-holding-n-v-reach-agreement-on-intended-public-offer-for-100-of-prosensas-outstanding-stock-will-add-duchenne-muscular-dystrophy-products-to-rare-disease-portfolio/</loc>
		<lastmod>2014-11-24T13:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-analyst-and-investor-day-on-december-10th-in-new-york/</loc>
		<lastmod>2014-12-03T13:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-vimizimr-elosulfase-alfa-approved-in-australia-for-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2014-12-07T13:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-analyst-and-investor-day-on-december-10th-in-new-york/</loc>
		<lastmod>2014-12-09T13:06:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-vimizimr-elosulfase-alfa-approved-in-brazil-for-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2014-12-10T13:06:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-prosensa-announce-expiration-of-the-hart-scott-rodino-waiting-period-for-biomarins-proposed-acquisition-of-prosensa/</loc>
		<lastmod>2014-12-24T13:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-approval-of-vimizimr-elosulfase-alfa-in-japan-for-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2014-12-29T13:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-planned-changes-to-board-of-directors-leadership-structure/</loc>
		<lastmod>2015-01-07T13:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-preliminary-data-from-ongoing-phase-1-2-pivotal-study-of-bmn-190-for-treatment-of-cln2-disorder-a-form-of-batten-disease/</loc>
		<lastmod>2015-01-12T13:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-completion-of-tender-offer-for-prosensas-shares-and-commences-subsequent-offering-period/</loc>
		<lastmod>2015-01-15T13:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-public-offering-of-common-stock-2/</loc>
		<lastmod>2015-01-21T13:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-public-offering-of-common-stock-2/</loc>
		<lastmod>2015-01-22T13:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-underwriters-full-exercise-of-option-to-purchase-additional-shares/</loc>
		<lastmod>2015-01-23T13:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-final-results-of-tender-offer-for-prosensas-shares-and-completion-of-subsequent-offering-period/</loc>
		<lastmod>2015-01-30T13:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2014-financial-results-conference-call-and-webcast-on-wednesday-february-25-at-430pm-et/</loc>
		<lastmod>2015-02-03T13:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-2-oral-and-8-poster-presentations-at-lysosomal-disease-networks-11th-annual-world-symposiumtm/</loc>
		<lastmod>2015-02-09T13:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3/</loc>
		<lastmod>2015-02-20T13:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2014-financial-results/</loc>
		<lastmod>2015-02-25T13:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2/</loc>
		<lastmod>2015-03-18T13:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-one-oral-and-7-poster-presentations-at-the-2015-american-college-of-medical-genetics-and-genomics-annual-clinical-genetics-meeting/</loc>
		<lastmod>2015-03-30T13:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2015-financial-results-conference-call-and-webcast-on-thursday-april-30-at-430pm-et/</loc>
		<lastmod>2015-04-14T13:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/</loc>
		<lastmod>2015-04-21T13:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-data-on-duchenne-muscular-dystrophy-at-the-67th-american-academy-of-neurology-annual-meeting/</loc>
		<lastmod>2015-04-23T12:59:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-rolling-nda-submission-to-fda-for-drisapersen-for-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-04-27T12:59:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2015-financial-results-and-company-update/</loc>
		<lastmod>2015-04-30T12:59:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-management-to-present-at-the-deutsche-bank-40th-annual-health-care-conference-on-may-6th-bank-of-america-merrill-lynch-2015-health-care-conference-on-may-13th-and-the-ubs-global-healthcare/</loc>
		<lastmod>2015-05-01T12:58:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/jean-jacques-bienaime-ceo-of-biomarin-to-present-at-the-goldman-sachs-36th-annual-global-healthcare-conference/</loc>
		<lastmod>2015-06-04T12:58:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-drisapersen-maa-to-ema-for-the-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-06-08T12:57:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-ceo-jean-jacques-bienaime-awarded-ey-entrepreneur-of-the-yearr-2015-award-in-northern-california-in-health-and-life-sciences/</loc>
		<lastmod>2015-06-15T12:57:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/bmn-111-vosoritide-improves-growth-velocity-in-children-with-achondroplasia-in-phase-2-study/</loc>
		<lastmod>2015-06-17T12:57:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-ema-validates-maa-for-drisapersen-for-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-06-25T12:56:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-accepts-drisapersen-nda-for-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-06-29T12:56:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2015-financial-results-conference-call-and-webcast-on-monday-august-3-at-430pm-et/</loc>
		<lastmod>2015-07-15T12:56:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-program-update-for-talazoparib-in-metastatic-breast-cancer/</loc>
		<lastmod>2015-07-20T12:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-joins-the-nasdaq-100-index/</loc>
		<lastmod>2015-07-27T12:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2015-financial-results-and-company-update/</loc>
		<lastmod>2015-08-03T12:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-rare-pediatric-disease-designation-from-fda-for-drisapersen-for-the-potential-treatment-of-duchenne-muscular-dystrophy/</loc>
		<lastmod>2015-08-19T12:54:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/forbes-ranks-biomarin-10th-most-innovative-company-in-the-world-2/</loc>
		<lastmod>2015-08-19T12:57:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/medivation-to-expand-global-oncology-franchise-with-the-acquisition-of-all-worldwide-rights-to-talazoparib-bmn-673-a-potent-parp-inhibitor-from-biomarin/</loc>
		<lastmod>2015-08-24T12:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-two-oral-and-19-poster-presentations-at-the-society-for-the-study-of-inborn-errors-of-metabolism-2015-annual-meeting/</loc>
		<lastmod>2015-08-31T12:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-launches-knowyourduchenne-comprehensive-program-for-patients-with-duchenne-muscular-dystrophy-to-understand-their-genetic-mutation/</loc>
		<lastmod>2015-09-01T12:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conferences-in-september/</loc>
		<lastmod>2015-09-02T12:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-kuvanr-sapropterin-dihydrochloride-patent-challenge-settlement/</loc>
		<lastmod>2015-09-18T12:52:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-enrolls-first-patient-in-phase-1-2-trial-of-gene-therapy-drug-candidate-bmn-270-for-the-treatment-of-hemophilia-a/</loc>
		<lastmod>2015-09-28T12:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-favorable-ruling-in-the-use-of-exon-51-antisense-oligonucleotides-patent-interference/</loc>
		<lastmod>2015-09-29T12:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-research-results-on-duchenne-muscular-dystrophy-and-pompe-disease-programs-at-the-20th-international-congress-of-the-world-muscle-society/</loc>
		<lastmod>2015-09-30T12:51:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-acquire-rights-to-phenylketonuria-pku-franchise-from-merck-serono/</loc>
		<lastmod>2015-10-01T12:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-initial-6-month-data-from-phase-2-study-of-vosoritide-bmn-111-in-children-with-achondroplasia-presented-at-the-american-society-for-bone-and-mineral-research-annual-2015-meeting/</loc>
		<lastmod>2015-10-12T12:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-advisory-committee-to-review-drisapersen-for-treatment-of-patients-with-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-10-15T12:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2015-financial-results-conference-call-and-webcast-on-thursday-october-29-at-430pm-et/</loc>
		<lastmod>2015-10-15T12:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conference-in-november/</loc>
		<lastmod>2015-10-27T12:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2015-financial-results-and-company-update/</loc>
		<lastmod>2015-10-29T12:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/ernst-young-names-biomarin-ceo-jean-jacques-bienaime-ey-entrepreneur-of-the-year-2015-national-award-winner-in-life-sciences/</loc>
		<lastmod>2015-11-16T12:48:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-posts-briefing-documents-for-advisory-committee-meeting-to-review-kyndrisa-drisapersen-for-the-potential-treatment-of-duchenne-muscular-dystrophy-amendable-to-exon-51-skipping/</loc>
		<lastmod>2015-11-20T00:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-data-analysis-demonstrating-consistent-efficacy-of-kyndrisa-drisapersen-in-comparable-patients-across-three-randomized-studies/</loc>
		<lastmod>2015-11-20T12:47:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/nice-recommends-biomarins-vimizim-elosulfase-alfa-for-the-treatment-of-morquio-a-syndrome-in-england/</loc>
		<lastmod>2015-11-23T12:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-posts-presentation-from-fda-advisory-committee-meeting-for-kyndrisatm-drisapersen-for-the-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-11-24T10:46:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-advisory-committee-discusses-clinical-data-package-for-biomarins-kyndrisatm-drisapersen-for-the-treatment-of-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2015-11-24T12:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pharmaceutical-inc-nasdaqbmrn-announced-today-the-stock-is-halted/</loc>
		<lastmod>2015-11-24T12:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-that-fda-has-advised-it-will-not-take-action-on-the-kyndrisa-drisapersen-new-drug-application-by-the-pdufa-date/</loc>
		<lastmod>2015-12-18T11:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-addition-of-david-pyott-former-allergan-chairman-and-ceo-to-companys-board-of-directors/</loc>
		<lastmod>2016-01-04T11:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-34th-annual-j-p-morgan-healthcare-conference-in-san-francisco/</loc>
		<lastmod>2016-01-05T11:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-interim-analysis-of-inspire-clinical-trial-in-pompe-disease-at-34th-annual-j-p-morgan-annual-healthcare-conference/</loc>
		<lastmod>2016-01-11T11:25:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-issues-complete-response-letter-for-kyndrisatm-for-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping/</loc>
		<lastmod>2016-01-14T11:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2015-financial-results-conference-call-and-webcast-on-thursday-february-25-at-430pm-et/</loc>
		<lastmod>2016-01-28T11:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2015-financial-results/</loc>
		<lastmod>2016-02-25T11:23:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-biomarin-rareconnections-rebranding-and-consolidating-biomarins-comprehensive-support-and-services-for-eligible-rare-disease-patients/</loc>
		<lastmod>2016-02-29T11:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-21-presentations-at-12th-annual-worldsymposium-2016-february-29-march-4-in-san-diego-california-6-oral-and-15-poster/</loc>
		<lastmod>2016-02-29T11:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-orphan-drug-designation-from-fda-for-first-aav-factor-viii-gene-therapy-bmn-270-for-patients-with-hemophilia-a/</loc>
		<lastmod>2016-03-01T11:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-data-from-cerliponase-alfa-program-for-treatment-of-cln2-disease-a-form-of-batten-disease-at-12th-annual-worldsymposiumtm-2016/</loc>
		<lastmod>2016-03-02T11:21:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-three-upcoming-investor-conferences-in-march/</loc>
		<lastmod>2016-03-03T11:19:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-phase-3-study-of-pegvaliase-for-phenylketonuria-pku-meets-primary-endpoint-of-blood-phenylalanine-phe-reduction-p0-0001/</loc>
		<lastmod>2016-03-21T11:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-european-orphan-drug-designation-for-bmn-270-first-investigational-aav-factor-viii-gene-therapy-for-patients-with-hemophilia-a/</loc>
		<lastmod>2016-03-24T11:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2016-financial-results-conference-call-and-webcast-on-thursday-april-28-at-430pm-et/</loc>
		<lastmod>2016-04-12T11:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-rd-day-on-april-20th-in-new-york/</loc>
		<lastmod>2016-04-18T11:17:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-encouraging-preliminary-data-on-first-8-patients-in-hemophilia-a-gene-therapy-program/</loc>
		<lastmod>2016-04-20T11:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-program-update-on-vosoritide-in-achondroplasia/</loc>
		<lastmod>2016-04-20T23:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-enrolls-first-patient-in-phase-1-2-trial-of-naglu-fusion-protein-bmn-250-for-treatment-of-mps-iiib-sanfilippo-b-syndrome/</loc>
		<lastmod>2016-04-21T11:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2016-financial-results/</loc>
		<lastmod>2016-04-28T11:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-ema-grants-accelerated-assessment-for-cerliponase-alfa-experimental-treatment-for-a-form-of-batten-disease/</loc>
		<lastmod>2016-05-03T11:14:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conferences-3/</loc>
		<lastmod>2016-05-04T11:14:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-withdrawal-of-market-authorization-application-for-kyndrisa-drisapersen-in-europe/</loc>
		<lastmod>2016-05-31T11:14:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-acceptance-of-late-breaking-abstract-for-bmn-270-at-the-world-federation-of-hemophilia-wfh-2016-world-congress-july-27-in-orlando-fl/</loc>
		<lastmod>2016-06-20T11:13:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2016-financial-results-conference-call-and-webcast-on-thursday-august-4-at-430pm-et/</loc>
		<lastmod>2016-07-14T11:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-two-biopharmaceutical-veterans-to-board-of-directors-willard-dere-m-d-and-kathryn-e-falberg/</loc>
		<lastmod>2016-07-18T11:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-provide-updated-data-for-bmn-270-in-hemophilia-a-in-late-breaking-oral-presentation-at-the-world-federation-of-hemophilia-wfh-2016-world-congress-july-27th/</loc>
		<lastmod>2016-07-21T11:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-positive-proof-of-concept-data-for-bmn-270-gene-therapy-in-hemophilia-a-in-late-breaking-oral-presentation-at-the-world-federation-of-hemophilia-wfh-2016-world-congress/</loc>
		<lastmod>2016-07-27T11:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-accepts-bla-for-biomarins-cerliponase-alfa-for-cln2-disease-form-of-batten-disease/</loc>
		<lastmod>2016-07-27T23:11:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2016-financial-results/</loc>
		<lastmod>2016-08-04T11:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-public-offering-of-common-stock/</loc>
		<lastmod>2016-08-08T11:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-public-offering-of-common-stock/</loc>
		<lastmod>2016-08-09T11:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/forbes-ranks-biomarin-10th-most-innovative-company-in-the-world/</loc>
		<lastmod>2016-08-24T11:09:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conferences-2/</loc>
		<lastmod>2016-08-31T11:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-update-to-brineura-cerliponase-alfa-program-for-treatment-of-cln2-disease-a-form-of-batten-disease/</loc>
		<lastmod>2016-09-06T11:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-two-oral-and-16-poster-presentations-at-society-for-the-study-of-inborn-errors-of-metabolism-2016-annual-meeting/</loc>
		<lastmod>2016-09-08T11:08:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-ema-validation-of-brineura-cerliponase-alfa-marketing-authorization-application-for-treatment-of-cln2-disease-a-form-of-batten-disease/</loc>
		<lastmod>2016-09-14T11:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-reviews-status-of-exon-51-composition-of-matter-and-method-of-use-patent-interference-cases-against-sarepta-therapeutics/</loc>
		<lastmod>2016-09-21T11:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2016-financial-results-conference-call-and-webcast-on-thursday-october-27-at-430pm-et/</loc>
		<lastmod>2016-10-11T11:06:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/uk-regulatory-agency-approves-continued-enrollment-in-biomarin-phase-1-2-study-of-bmn-270-in-hemophilia-a/</loc>
		<lastmod>2016-10-13T11:06:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-vosoritide-data-in-achondroplasia-at-american-society-of-human-genetics-ashg-2016-meeting/</loc>
		<lastmod>2016-10-19T11:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2016-financial-results/</loc>
		<lastmod>2016-10-27T11:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-three-upcoming-investor-conferences-2/</loc>
		<lastmod>2016-11-03T10:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-enrolls-first-participant-in-phase-3-trial-of-vosoritide-for-treatment-of-children-with-achondroplasia/</loc>
		<lastmod>2016-12-12T10:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-35th-annual-j-p-morgan-healthcare-conference-in-san-francisco/</loc>
		<lastmod>2017-01-03T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-provide-update-to-proof-of-concept-data-for-bmn-270-gene-therapy-in-hemophilia-a-at-35th-annual-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2017-01-08T19:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-access-to-priority-medicines-prime-regulatory-support-from-ema-for-bmn-270-gene-therapy-in-hemophilia-a/</loc>
		<lastmod>2017-02-01T16:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2016-financial-results-conference-call-and-webcast-on-thursday-february-23-at-430pm-et/</loc>
		<lastmod>2017-02-07T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-three-investor-conferences-in-1q17/</loc>
		<lastmod>2017-02-08T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-11-presentations-at-13th-annual-worldsymposium-2017/</loc>
		<lastmod>2017-02-15T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2016-financial-results/</loc>
		<lastmod>2017-02-23T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-kuvan-sapropterin-dihydrochloride-patent-challenge-settlement/</loc>
		<lastmod>2017-04-13T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2017-financial-results-conference-call-and-webcast-on-thursday-may-4-at-430pm-et/</loc>
		<lastmod>2017-04-20T16:53:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-chmp-opinion-in-europe-for-brineura-cerliponase-alfa-for-first-treatment-of-cln2-disease-a-form-of-batten-disease-and-ultra-rare-and-fatal-brain-disorder-in-chil/</loc>
		<lastmod>2017-04-21T13:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-approves-brineura-cerliponase-alfa-for-the-treatment-of-cln2-disease-a-form-of-batten-disease-and-ultra-rare-pediatric-brain-disorder-in-children/</loc>
		<lastmod>2017-04-27T13:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-two-upcoming-investor-conferences/</loc>
		<lastmod>2017-05-02T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2017-financial-results/</loc>
		<lastmod>2017-05-04T16:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conference-3/</loc>
		<lastmod>2017-05-31T06:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-commission-approves-brineura-cerliponase-alfa-the-first-treatment-for-cln2-disease-a-form-of-batten-disease-and-ultra-rare-brain-disorder-in-children/</loc>
		<lastmod>2017-06-01T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-acceptance-of-late-breaking-abstract-at-the-international-society-on-thrombosis-and-haemostasis-2017-congress/</loc>
		<lastmod>2017-06-16T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-pegvaliase-biologics-license-application-bla-to-the-u-s-fda-for-treatment-of-phenylketonuria-pku/</loc>
		<lastmod>2017-06-30T09:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-investigational-gene-therapy-for-hemophilia-a-at-6e13-vg-kg-dose-maintains-average-factor-viii-levels-within-normal-range-for-over-one-year/</loc>
		<lastmod>2017-07-11T03:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/sarepta-therapeutics-and-biomarin-pharmaceutical-inc-announce-execution-of-a-global-settlement-and-a-license-agreement-resolving-exon-skipping-patent-litigation/</loc>
		<lastmod>2017-07-18T01:43:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-plans-to-progress-both-the-6e13vg-kg-and-4e13-vg-kg-doses-of-bmn-270-its-investigational-gene-therapy-for-hemophilia-a-into-phase-3-studies/</loc>
		<lastmod>2017-08-02T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2017-financial-results/</loc>
		<lastmod>2017-08-02T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-offering-of-450-million-of-senior-subordinated-convertible-notes-due-2024/</loc>
		<lastmod>2017-08-07T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conferences/</loc>
		<lastmod>2017-08-15T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/forbes-ranks-biomarin-12th-most-innovative-company-in-the-world/</loc>
		<lastmod>2017-08-21T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-exercise-in-full-of-underwriters-option-to-purchase-additional-0-599-senior-subordinated-convertible-notes-due-2024/</loc>
		<lastmod>2017-08-23T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-accepts-biomarins-pegvaliase-biologics-license-application-bla-and-grants-priority-review-designation/</loc>
		<lastmod>2017-08-29T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-3-platform-and-15-poster-presentations-at-13th-international-congress-of-inborn-errors-of-metabolism-2017/</loc>
		<lastmod>2017-09-05T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-interim-data-of-phase-1-2-study-of-bmn-250-for-treatment-of-sanfilippo-b-syndrome-mps-iiib-at-13th-international-congress-of-inborn-errors-of-metabolism-iciem-2017/</loc>
		<lastmod>2017-09-06T11:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-not-currently-planning-to-hold-advisory-committee-meeting-for-biomarins-pegvaliase-biologics-license-application-bla/</loc>
		<lastmod>2017-09-14T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-robert-j-hombach-former-baxalta-cfo-and-coo-to-board-of-directors/</loc>
		<lastmod>2017-10-03T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2017-financial-results-conference-call-and-webcast-on-thursday-october-26-at-430-p-m-et/</loc>
		<lastmod>2017-10-10T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-rd-day-on-october-18th-in-new-york/</loc>
		<lastmod>2017-10-11T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/popular-science-names-biomarins-brineura-cerliponase-alfa-one-of-the-top-health-innovations-of-2017-with-best-of-whats-new-award/</loc>
		<lastmod>2017-10-18T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-highlights-breadth-of-innovative-development-pipeline-at-rd-day-on-october-18th-in-new-york/</loc>
		<lastmod>2017-10-18T12:24:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-grants-breakthrough-therapy-designation-for-biomarins-valoctocogene-roxaparvovec-formerly-bmn-270-an-investigational-gene-therapy-for-hemophilia-a/</loc>
		<lastmod>2017-10-26T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2017-financial-results/</loc>
		<lastmod>2017-10-26T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-three-upcoming-investor-conferences/</loc>
		<lastmod>2017-10-31T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-sells-second-priority-review-voucher-for-125-million/</loc>
		<lastmod>2017-11-27T08:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-presentations-at-59th-american-society-of-hematology-annual-meeting-exposition/</loc>
		<lastmod>2017-12-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-1-5-years-of-clinical-data-for-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a-at-59th-american-society-of-hematology-ash-annual-meeting-concurrent-with-nejm-public/</loc>
		<lastmod>2017-12-09T07:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-highlights-new-results-for-gene-therapy-valoctocogene-roxaparvovec-at-the-2017-american-society-of-hemophilia-ash-meeting/</loc>
		<lastmod>2017-12-11T10:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-doses-first-patient-in-global-gener8-1-phase-3-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a/</loc>
		<lastmod>2017-12-19T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-anticipated-notification-of-pdufa-extension-for-pegvaliase-biologics-license-application-bla-to-may-28-2018/</loc>
		<lastmod>2017-12-22T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-36th-annual-j-p-morgan-healthcare-conference-in-san-francisco/</loc>
		<lastmod>2018-01-03T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-and-webcast-on-thursday-february-22-at-430pm-et/</loc>
		<lastmod>2018-01-24T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-20-presentations-at-14th-annual-worldsymposium-2018/</loc>
		<lastmod>2018-02-05T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/worldsymposium-recognizes-biomarins-brineura-cerliponase-alfa-with-2018-new-treatment-award/</loc>
		<lastmod>2018-02-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-interim-data-of-phase-1-2-study-of-bmn-250-for-treatment-of-sanfilippo-b-syndrome-mps-iiib-at-worldsymposium-2018/</loc>
		<lastmod>2018-02-07T12:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2017-financial-results/</loc>
		<lastmod>2018-02-22T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/rare-disease-day-2018-biomarin-launches-rare-scholars-scholarship-program/</loc>
		<lastmod>2018-02-28T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conference-2/</loc>
		<lastmod>2018-03-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-gene-therapy-manufacturing-facility-recognized-with-industry-award/</loc>
		<lastmod>2018-03-21T08:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-medicines-agency-ema-accepts-biomarins-marketing-application-for-pegvaliase-maa-for-treatment-of-phenylketonuria-pku/</loc>
		<lastmod>2018-03-28T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2018-financial-results-conference-call-and-webcast-on-wednesday-april-25-at-430pm-et/</loc>
		<lastmod>2018-04-18T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-alfa-reduced-the-rate-of-clinical-decline-of-children-with-cln2-disease-a-form-of-batten-disease/</loc>
		<lastmod>2018-04-24T14:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2018-financial-results/</loc>
		<lastmod>2018-04-25T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-named-to-forbes-list-of-americas-best-mid-size-employers/</loc>
		<lastmod>2018-05-01T12:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-attend-upcoming-investor-conference/</loc>
		<lastmod>2018-05-02T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-patient-dosed-in-phase-1-2-study-evaluating-valoctocogene-roxaparvovec-gene-therapy-in-severe-hemophilia-a-patients-with-pre-existing-aav5-antibodies/</loc>
		<lastmod>2018-05-15T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-1-platform-and-3-poster-presentations-at-world-federation-of-hemophilia-2018-world-congress/</loc>
		<lastmod>2018-05-17T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-2-years-of-clinical-data-in-6e13-vg-kg-dose-from-ongoing-phase-1-2-study-in-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a-at-world-federation-of-hemophilia-2018-wor/</loc>
		<lastmod>2018-05-22T07:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-standard-approval-for-palynziq-pegvaliase-pqpz-injection-for-treatment-of-adults-with-phenylketonuria-pku-a-rare-genetic-disease/</loc>
		<lastmod>2018-05-24T17:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-milestone-payments-from-pfizer-for-talazoparib/</loc>
		<lastmod>2018-06-07T08:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-doses-first-participant-in-phase-2-study-of-vosoritide-for-treatment-of-infants-and-young-children-with-achondroplasia/</loc>
		<lastmod>2018-06-14T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-recipients-of-rare-scholars-scholarship-program/</loc>
		<lastmod>2018-06-28T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-partners-with-believe-limited-for-breaking-through-musical-theater-intensive/</loc>
		<lastmod>2018-07-09T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2018-financial-results-conference-call-and-webcast-on-thursday-august-2-at-430pm-et/</loc>
		<lastmod>2018-07-11T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2018-results/</loc>
		<lastmod>2018-08-02T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-three-investor-conferences-in-september/</loc>
		<lastmod>2018-08-22T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-20-poster-presentations-at-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-symposium-2018/</loc>
		<lastmod>2018-09-05T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-investor-conferences-in-october/</loc>
		<lastmod>2018-09-19T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2018-financial-results-conference-call-and-webcast-on-thursday-october-25-at-430pm-et/</loc>
		<lastmod>2018-10-04T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/forbes-names-biomarin-among-worlds-best-employers/</loc>
		<lastmod>2018-10-11T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-believe-limited-announce-selection-of-25-high-school-students-to-perform-in-first-of-its-kind-hemophilia-the-musical/</loc>
		<lastmod>2018-10-11T17:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-milestone-payments-from-pfizer-for-talzenna-talazoparib-for-metastatic-breast-cancer-patients-with-an-inherited-brca-mutation/</loc>
		<lastmod>2018-10-16T12:58:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2018-results/</loc>
		<lastmod>2018-10-25T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-rd-day-on-november-7th-in-new-york/</loc>
		<lastmod>2018-11-01T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-highlights-breadth-of-innovative-development-pipeline-at-rd-day-on-november-7th-in-new-york/</loc>
		<lastmod>2018-11-07T09:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-investor-conferences-in-november/</loc>
		<lastmod>2018-11-08T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-believe-limited-announce-the-debut-of-hemophilia-the-musical/</loc>
		<lastmod>2018-11-12T01:22:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-citis-13th-annual-biotech-conference-on-december-5-in-new-york-city/</loc>
		<lastmod>2018-12-03T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-highlights-key-milestones-for-2019-at-37th-annual-j-p-morgan-healthcare-conference-in-san-francisco/</loc>
		<lastmod>2019-01-07T11:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2018-financial-results-conference-call-and-webcast-on-thursday-february-21-at-430pm-et/</loc>
		<lastmod>2019-01-23T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-14-presentations-at-15th-annual-worldsymposium-2019/</loc>
		<lastmod>2019-02-04T08:35:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-ongoing-study-demonstrates-durable-treatment-benefit-from-brineura-cerliponase-alfa-for-3-years/</loc>
		<lastmod>2019-02-07T16:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-full-year-and-fourth-quarter-2018-results/</loc>
		<lastmod>2019-02-21T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-chmp-opinion-in-europe-for-palynziq-pegvaliase-injection-for-treatment-of-patients-with-phenylketonuria-pku-aged-16-and-older/</loc>
		<lastmod>2019-03-01T07:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-cowen-and-company-39th-annual-health-care-conference-on-march-12-in-boston/</loc>
		<lastmod>2019-03-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2019-financial-results-conference-call-and-webcast-on-thursday-april-25-at-430pm-et/</loc>
		<lastmod>2019-04-02T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/forbes-names-biomarin-4th-best-midsize-employer-in-america/</loc>
		<lastmod>2019-04-17T11:18:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2019-financial-results/</loc>
		<lastmod>2019-04-25T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-commission-approves-palynziq-pegvaliase-injection-for-treatment-of-phenylketonuria-pku-in-patients-aged-16-years-or-older/</loc>
		<lastmod>2019-05-06T10:12:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-on-may-15-in-las-vegas/</loc>
		<lastmod>2019-05-08T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-2019-rbc-capital-markets-global-healthcare-conference-on-may-21-in-new-york-city/</loc>
		<lastmod>2019-05-16T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-conference-call-tuesday-may-28-2019-to-provide-a-valoctocogene-roxaparvovec-phase-2-and-phase-3-update/</loc>
		<lastmod>2019-05-27T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-3-years-of-clinical-data-from-ongoing-phase-1-2-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a/</loc>
		<lastmod>2019-05-28T06:50:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-that-phase-3-cohort-of-valoctocogene-roxaparvovec-gene-therapy-study-in-severe-hemophilia-a-met-pre-specified-criteria-for-regulatory-submissions-in-the-u-s-and-europe/</loc>
		<lastmod>2019-05-28T06:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-approval-of-vimizim-elosulfase-alfa-in-china-for-treatment-of-morquio-a-syndrome/</loc>
		<lastmod>2019-06-04T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-goldman-sachs-40th-annual-global-healthcare-conference-on-tuesday-june-11-in-rancho-palos-verdes-ca/</loc>
		<lastmod>2019-06-05T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-new-england-journal-of-medicine-publishes-vosoritide-phase-2-study-showing-sustained-annualized-growth-up-to-42-months-in-children-with-achondroplasia/</loc>
		<lastmod>2019-06-18T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-earns-milestone-payments-from-pfizer-for-talzenna-talazoparib-for-metastatic-breast-cancer-patients-with-an-inherited-brca-mutation/</loc>
		<lastmod>2019-06-21T11:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-acceptance-of-late-breaking-abstract-at-the-international-society-on-thrombosis-and-haemostasis-isth-2019-congress-in-melbourne-australia-from-july-6-10-2019/</loc>
		<lastmod>2019-06-26T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-plans-regulatory-submissions-for-marketing-authorization-of-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a-in-4q-2019-in-both-u-s-and-europe/</loc>
		<lastmod>2019-07-08T08:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-pharmaceutical-veteran-and-former-j-j-executive-liz-mckee-anderson-to-board-of-directors/</loc>
		<lastmod>2019-07-09T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2019-financial-results-conference-call-and-webcast-on-thursday-august-1-at-430pm-et/</loc>
		<lastmod>2019-07-16T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2019-financial-results/</loc>
		<lastmod>2019-08-01T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-on-september-10-2019-in-new-york-2/</loc>
		<lastmod>2019-08-28T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-morgan-stanley-17th-annual-global-healthcare-conference-on-september-10-2019-in-new-york/</loc>
		<lastmod>2019-09-09T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pioneer-in-phenylketonuria-pku-therapies-submits-clinical-trial-application-cta-in-u-k-for-investigational-gene-therapy-for-pku/</loc>
		<lastmod>2019-09-26T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-jefferies-gene-therapy-editing-summit-on-october-8-2019-in-new-york/</loc>
		<lastmod>2019-10-01T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-promotes-lon-cardon-ph-d-to-chief-scientific-strategy-officer/</loc>
		<lastmod>2019-10-07T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2019-financial-results-conference-call-and-webcast-on-wednesday-october-23-at-430pm-et/</loc>
		<lastmod>2019-10-09T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2019-financial-results/</loc>
		<lastmod>2019-10-23T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-highlight-innovative-development-pipeline-at-rd-day-on-november-14th/</loc>
		<lastmod>2019-11-06T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-jefferies-london-healthcare-conference-on-november-21-2019/</loc>
		<lastmod>2019-11-12T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-cumulative-additional-height-gain-of-9-0-cm-over-54-months-versus-natural-history-in-children-with-achondroplasia-treated-with-vosoritide-in-phase-2-study/</loc>
		<lastmod>2019-11-14T08:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/poised-for-significant-growth-and-profitability-biomarin-shares-company-highlights-during-rd-day-on-november-14th-in-new-york/</loc>
		<lastmod>2019-11-14T11:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a/</loc>
		<lastmod>2019-11-21T16:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-final-results-from-placebo-controlled-phase-3-data-in-children-with-achondroplasia-treated-with-vosoritide/</loc>
		<lastmod>2019-12-16T08:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-valoctocogene-roxaparvovec-to-treat-hemophilia-a/</loc>
		<lastmod>2019-12-23T08:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-new-england-journal-of-medicine-publishes-3-years-of-follow-up-data-in-phase-1-2-study-of-valoctocogene-roxaparvovec-gene-therapy-for-hemophilia-a/</loc>
		<lastmod>2020-01-02T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-38th-annual-j-p-morgan-healthcare-conference-in-san-francisco/</loc>
		<lastmod>2020-01-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-goldman-sachs-12th-annual-healthcare-ceos-unscripted-a-view-from-the-top-on-january-9-2020-in-new-york/</loc>
		<lastmod>2020-01-08T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pioneer-in-phenylketonuria-to-begin-clinical-trial-with-bmn-307-gene-therapy/</loc>
		<lastmod>2020-01-13T08:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2019-financial-results-conference-call-and-webcast-on-wednesday-february-26-at-430pm-et/</loc>
		<lastmod>2020-01-29T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-cfo-succession/</loc>
		<lastmod>2020-02-03T16:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-investor-conferences-2/</loc>
		<lastmod>2020-02-12T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-biologics-license-application-for-valoctocogene-roxaparvovec-accepted-for-priority-review-by-fda-with-review-action-date-of-august-21-2020/</loc>
		<lastmod>2020-02-20T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-record-full-year-2019-financial-results/</loc>
		<lastmod>2020-02-26T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-brinda-balakrishnan-m-d-ph-d-honored-with-2020-40-under-40-award-from-the-san-francisco-business-times/</loc>
		<lastmod>2020-03-09T15:10:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-plans-regulatory-submissions-for-marketing-authorization-of-vosoritide-to-treat-children-with-achondroplasia-in-3q-2020-in-both-us-and-europe/</loc>
		<lastmod>2020-04-06T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2020-financial-results-conference-call-and-webcast-on-thursday-april-30-at-430pm-et/</loc>
		<lastmod>2020-04-14T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-global-pharmaceutical-veteran-c-greg-guyer-ph-d-to-chief-technical-officer-executive-vice-president-of-global-manufacturing-and-technical-operations-effective-may-4/</loc>
		<lastmod>2020-04-21T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-updates-timing-of-first-quarter-2020-financial-results-conference-call-and-webcast-to-wednesday-april-29-at-415pm-et/</loc>
		<lastmod>2020-04-22T16:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2020-total-revenue-growth-of-25-to-502-million/</loc>
		<lastmod>2020-04-29T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-extends-gene-therapy-leadership-with-dinaqor-in-a-preclinical-collaboration-and-license-agreement-to-develop-gene-therapies-for-rare-genetic-cardiomyopathies/</loc>
		<lastmod>2020-05-03T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-11/</loc>
		<lastmod>2020-05-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-proposed-private-offering-of-500-million-of-senior-subordinated-convertible-notes/</loc>
		<lastmod>2020-05-11T07:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-pricing-of-upsized-550-million-senior-subordinated-convertible-notes-offering/</loc>
		<lastmod>2020-05-11T23:26:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-closing-of-exercise-by-initial-purchasers-of-option-to-purchase-an-additional-50-million-of-1-25-senior-subordinated-convertible-notes-due-2027/</loc>
		<lastmod>2020-05-19T16:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-highlights-of-4-years-of-clinical-data-from-ongoing-phase-1-2-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a/</loc>
		<lastmod>2020-05-31T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-10/</loc>
		<lastmod>2020-06-03T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-additional-data-from-recent-4-year-update-of-ongoing-phase-1-2-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a-in-late-breaking-oral-presentation-at-world-fe/</loc>
		<lastmod>2020-06-17T09:20:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-the-virtual-bofa-securities-2020-napa-biopharma-conference/</loc>
		<lastmod>2020-06-23T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-promotes-company-veteran-brian-r-mueller-to-executive-vice-president-cfo/</loc>
		<lastmod>2020-06-29T16:16:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2020-financial-results-conference-call-and-webcast-on-tuesday-august-4-at-430pm-et/</loc>
		<lastmod>2020-07-21T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-marketing-authorization-application-to-european-medicines-agency-for-vosoritide-to-treat-children-with-achondroplasia/</loc>
		<lastmod>2020-07-23T16:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2020-total-revenue-growth-of-11-to-430-million/</loc>
		<lastmod>2020-08-04T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-9/</loc>
		<lastmod>2020-08-10T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-medicines-agency-validates-biomarins-marketing-authorization-application-for-vosoritide-to-treat-children-with-achondroplasia/</loc>
		<lastmod>2020-08-13T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-complete-response-letter-crl-from-fda-for-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a/</loc>
		<lastmod>2020-08-19T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-submits-new-drug-application-to-u-s-food-and-drug-administration-for-vosoritide-to-treat-children-with-achondroplasia/</loc>
		<lastmod>2020-08-20T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-8/</loc>
		<lastmod>2020-09-08T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-the-lancet-publishes-detailed-vosoritide-phase-3-data-demonstrating-statistically-significant-increase-in-annualized-growth-velocity-agv-over-52-weeks-in-children-with-achondropla/</loc>
		<lastmod>2020-09-08T09:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-presentation-of-vosoritide-phase-3-data-in-children-with-achondroplasia-at-the-american-society-for-bone-and-mineral-research-2020-annual-meeting/</loc>
		<lastmod>2020-09-11T08:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-3/</loc>
		<lastmod>2020-09-15T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-doses-first-participant-in-global-phearless-phase-1-2-study-of-bmn-307-gene-therapy/</loc>
		<lastmod>2020-09-24T09:07:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-upcoming-virtual-investor-conference/</loc>
		<lastmod>2020-09-29T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-receives-fda-fast-track-designation-for-pku-investigational-gene-therapy-bmn-307/</loc>
		<lastmod>2020-10-02T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/scientific-luminary-and-macarthur-fellowship-winner-kevin-eggan-ph-d-joins-biomarin-as-head-of-research-and-early-development/</loc>
		<lastmod>2020-10-05T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-pioneer-in-rare-disease-treatments-for-phenylketonuria-pku-receives-fda-approval-of-label-expansion-to-allow-maximum-dose-of-60-mg-for-palynziq-pegvaliase-pqpz-injection-for-treat/</loc>
		<lastmod>2020-10-07T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2020-financial-results-conference-call-and-webcast-on-thursday-november-5-at-430pm-et/</loc>
		<lastmod>2020-10-22T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/food-and-drug-administration-accepts-biomarins-new-drug-application-for-vosoritide-to-treat-children-with-achondroplasia/</loc>
		<lastmod>2020-11-02T20:55:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-the-credit-suisse-29th-annual-virtual-healthcare-conference-on-november-10-at-1230pm-et/</loc>
		<lastmod>2020-11-04T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2020-total-revenues-of-477-million/</loc>
		<lastmod>2020-11-05T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-expands-vosoritide-clinical-program/</loc>
		<lastmod>2020-11-09T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-three-upcoming-virtual-investor-conferences-2/</loc>
		<lastmod>2020-11-12T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-deep-genomics-to-collaborate-on-advancing-programs-identified-using-artificial-intelligence/</loc>
		<lastmod>2020-11-17T08:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-7/</loc>
		<lastmod>2020-12-01T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-benefit-maintained-for-over-two-years-in-children-with-achondroplasia-treated-with-vosoritide-in-phase-3-extension-study/</loc>
		<lastmod>2020-12-21T08:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-6/</loc>
		<lastmod>2021-01-05T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-positive-phase-3-gene-therapy-trial-results-in-adults-with-severe-hemophilia-a-study-met-all-primary-and-secondary-efficacy-endpoints-in-one-year-data-set/</loc>
		<lastmod>2021-01-10T18:44:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast-on-thursday-february-25-at-430pm-et/</loc>
		<lastmod>2021-01-26T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-earns-top-marks-in-human-rights-campaigns-2021-corporate-equality-index/</loc>
		<lastmod>2021-01-28T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-former-goldman-sachs-partner-and-life-sciences-executive-maykin-ho-ph-d-to-board-of-directors/</loc>
		<lastmod>2021-02-18T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences-2/</loc>
		<lastmod>2021-02-24T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-record-full-year-2020-financial-results-and-corporate-updates/</loc>
		<lastmod>2021-02-25T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-completes-full-enrollment-in-phase-2-study-of-vosoritide-for-treatment-of-infants-and-young-children-with-achondroplasia/</loc>
		<lastmod>2021-03-03T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-valoctocogene-roxaparvovec-investigational-gene-therapy-for-hemophilia-a/</loc>
		<lastmod>2021-03-08T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-oral-presentation-at-endo2021-the-endocrine-societys-annual-meeting-with-data-demonstrating-2-years-of-treatment-benefit-in-children-with-achondroplasia-treated-with-vosoritide/</loc>
		<lastmod>2021-03-20T11:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2021-financial-results-conference-call-and-webcast-on-thursday-april-29-at-430pm-et/</loc>
		<lastmod>2021-04-13T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/allen-institute-and-biomarin-team-up-to-develop-gene-therapies-for-rare-brain-diseases/</loc>
		<lastmod>2021-04-28T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-quarter-2021-financial-results-and-corporate-updates/</loc>
		<lastmod>2021-04-29T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-5/</loc>
		<lastmod>2021-05-03T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-virtual-2021-annual-meeting/</loc>
		<lastmod>2021-05-12T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-4/</loc>
		<lastmod>2021-05-18T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-highlights-of-5-years-of-clinical-data-from-ongoing-phase-1-2-study-of-valoctocogene-roxaparvovec-with-the-longest-duration-of-clinical-experience-for-a-gene-therapy-in-hemophilia-a/</loc>
		<lastmod>2021-05-19T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-medicines-agency-grants-biomarins-request-for-accelerated-assessment-of-valoctocogene-roxaparvovec-for-treatment-of-severe-hemophilia-a/</loc>
		<lastmod>2021-05-24T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-3/</loc>
		<lastmod>2021-05-27T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-the-virtual-bofa-securities-2021-napa-biopharma-conference/</loc>
		<lastmod>2021-06-15T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-chmp-opinion-in-europe-for-vosoritide-for-the-treatment-of-children-with-achondroplasia-from-age-2-until-growth-plates-close/</loc>
		<lastmod>2021-06-25T07:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-resubmits-marketing-authorization-application-maa-to-european-medicines-agency-for-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a/</loc>
		<lastmod>2021-06-28T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-12-presentations-at-the-international-society-on-thrombosis-and-haemostasis-isth-2021-virtual-congress/</loc>
		<lastmod>2021-07-02T09:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2021-financial-results-conference-call-and-webcast-on-wednesday-july-28-at-430pm-et/</loc>
		<lastmod>2021-07-14T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-medicines-agency-validates-biomarins-marketing-authorization-application-for-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a/</loc>
		<lastmod>2021-07-15T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-oral-presentation-of-positive-one-year-results-from-phase-3-pivotal-trial-with-valoctocogene-roxaparvovec-gene-therapy-in-adults-with-severe-hemophilia-a-at-international-society-on/</loc>
		<lastmod>2021-07-19T11:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-oral-presentation-at-international-society-on-thrombosis-and-haemostasis-isth-2021-virtual-congress-with-5-years-of-clinical-data-from-ongoing-phase-1-2-study-of-valoctocogene-rox/</loc>
		<lastmod>2021-07-21T10:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2021-financial-results-and-corporate-updates/</loc>
		<lastmod>2021-07-28T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-three-upcoming-virtual-investor-conferences/</loc>
		<lastmod>2021-08-25T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-commission-approves-biomarins-voxzogo-vosoritide-for-the-treatment-of-children-with-achondroplasia-from-age-2-until-growth-plates-close/</loc>
		<lastmod>2021-08-27T09:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/u-s-fda-placed-a-clinical-hold-on-bmn-307-phearless-phase-1-2-gene-therapy-study-in-adults-with-pku-based-on-interim-pre-clinical-study-findings/</loc>
		<lastmod>2021-09-06T02:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-hires-industry-veterans-to-fill-key-roles-in-rd-and-technical-operations/</loc>
		<lastmod>2021-10-04T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2021-financial-results-conference-call-and-webcast-on-wednesday-october-27-at-430pm-et/</loc>
		<lastmod>2021-10-12T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-four-upcoming-virtual-investor-conferences/</loc>
		<lastmod>2021-10-25T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2021-financial-results-and-corporate-updates/</loc>
		<lastmod>2021-10-27T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-fda-approval-for-voxzogo-vosoritide-for-injection-indicated-to-increase-linear-growth-in-children-with-achondroplasia-aged-5-and-up-with-open-growth-plates/</loc>
		<lastmod>2021-11-19T10:42:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-2/</loc>
		<lastmod>2021-11-29T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-hold-virtual-rd-day-at-1100am-et-today/</loc>
		<lastmod>2021-11-30T08:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-former-ceo-of-celgene-corporation-mark-alles-to-board-of-directors/</loc>
		<lastmod>2021-12-15T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-skyline-therapeutics-announce-strategic-collaboration-to-develop-novel-gene-therapies-for-cardiovascular-diseases/</loc>
		<lastmod>2021-12-16T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-virtual-investor-conferences-in-january/</loc>
		<lastmod>2022-01-04T06:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-stable-and-durable-annualized-bleed-control-in-the-largest-phase-3-gene-therapy-study-in-adults-with-severe-hemophilia-a-134-participant-study-met-all-primary-and-secondary-efficac/</loc>
		<lastmod>2022-01-09T15:13:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-demonstrates-enduring-commitment-to-advancing-the-standard-of-care-in-hemophilia-a-at-15th-annual-congress-of-the-european-association-for-haemophilia-and-allied-disorders-eahad-february-2/</loc>
		<lastmod>2022-02-02T16:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-oral-presentation-of-2-year-analysis-of-largest-phase-3-gene-therapy-study-in-adults-with-severe-hemophilia-a-at-15th-annual-congress-of-european-association-for-haemophilia-and-all/</loc>
		<lastmod>2022-02-04T11:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-sells-priority-review-voucher-for-110-million/</loc>
		<lastmod>2022-02-09T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2021-financial-results-conference-call-and-webcast-on-wednesday-february-23-at-430pm-et/</loc>
		<lastmod>2022-02-10T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences/</loc>
		<lastmod>2022-02-16T16:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-updates-on-progress-in-gene-therapy-programs/</loc>
		<lastmod>2022-02-17T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-fourth-quarter-and-full-year-2021-financial-results-and-corporate-updates/</loc>
		<lastmod>2022-02-23T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-publication-in-new-england-journal-of-medicine-of-one-year-results-from-phase-3-pivotal-trial-with-valoctocogene-roxaparvovec-gene-therapy-in-adults-with-severe-hemophilia-a/</loc>
		<lastmod>2022-03-17T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2022-financial-results-conference-call-and-webcast-on-wednesday-april-27-at-430pm-et/</loc>
		<lastmod>2022-04-13T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-record-revenues-in-first-quarter-2022/</loc>
		<lastmod>2022-04-27T16:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-the-bofa-securities-2022-healthcare-conference-thursday-may-12-at-840ampt-1140amet/</loc>
		<lastmod>2022-05-04T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-hires-pharmaceutical-industry-leaders-in-marketing-and-accounting-to-fill-strategic-roles-supporting-companys-growth-plans/</loc>
		<lastmod>2022-05-05T16:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-durable-hemostatic-efficacy-maintained-over-6-years-in-ongoing-phase-1-2-study-of-valoctocogene-roxaparvovec-investigational-gene-therapy-for-hemophilia-a/</loc>
		<lastmod>2022-05-31T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-favorable-results-from-global-phase-2-study-of-voxzogo-vosoritide-for-injection-in-infants-and-young-children-with-achondroplasia-at-the-endocrine-society-annual-meeting/</loc>
		<lastmod>2022-06-13T12:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-the-ministry-of-health-labor-and-welfare-mhlw-in-japan-granted-approval-for-voxzogo-vosoritide-for-injection-for-the-treatment-of-children-with-achondroplasia-whose-grow/</loc>
		<lastmod>2022-06-21T16:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-chmp-opinion-in-europe-for-valoctocogene-roxaparvovec-gene-therapy-to-treat-adults-with-severe-hemophilia-a/</loc>
		<lastmod>2022-06-24T07:15:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-findings-from-studies-of-valoctocogene-roxaparvovec-investigational-gene-therapy-at-the-international-society-on-thrombosis-and-haemostasis-isth-2022-congress-july-9-12-includin/</loc>
		<lastmod>2022-07-11T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2022-financial-results-conference-call-and-webcast-on-wednesday-august-3-at-430pm-et/</loc>
		<lastmod>2022-07-20T13:49:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-record-revenues-in-second-quarter-2022-increases-full-year-2022-top-and-bottom-line-guidance/</loc>
		<lastmod>2022-08-03T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/first-gene-therapy-for-adults-with-severe-hemophilia-a-biomarins-roctavian-valoctocogene-roxaparvovec-approved-by-european-commission-ec/</loc>
		<lastmod>2022-08-24T16:36:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarins-gene-therapy-for-adults-with-severe-hemophilia-a-roctavian-valoctocogene-roxaparvovec-assessed-to-provide-substantial-cost-savings-per-patient-in-a-preliminary-independent-repo/</loc>
		<lastmod>2022-09-15T08:31:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-resubmits-biologics-license-application-bla-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-severe-hemophilia-a-to-the-fda/</loc>
		<lastmod>2022-09-29T16:04:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2022-financial-results-conference-call-and-webcast-on-wednesday-october-26-at-430pm-et/</loc>
		<lastmod>2022-10-04T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-simplifies-organizational-structure-to-increase-efficiency/</loc>
		<lastmod>2022-10-06T19:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-accepts-biomarins-biologics-license-application-bla-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-adults-with-severe-hemophilia-a/</loc>
		<lastmod>2022-10-12T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-third-quarter-2022-year-over-year-total-revenue-growth-of-24-31-excluding-kuvan/</loc>
		<lastmod>2022-10-26T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-two-upcoming-investor-conferences/</loc>
		<lastmod>2022-11-03T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-incremental-progress-on-biologics-license-application-bla-review-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-adults-with-severe-hemophilia-a-program/</loc>
		<lastmod>2022-11-07T16:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-advancements-in-fda-review-of-roctavian-valoctocogene-roxaparvovec-for-adults-with-severe-hemophilia-a/</loc>
		<lastmod>2022-11-23T08:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-medicines-agency-validates-application-for-extension-of-indication-for-voxzogo-vosoritide-for-injection-to-treat-children-with-achondroplasia-under-the-age-of-2/</loc>
		<lastmod>2023-01-03T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-41st-annual-j-p-morgan-healthcare-conference-on-monday-january-9-at-1030-am-pt-130-pm-et-in-san-francisco-ca/</loc>
		<lastmod>2023-01-04T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-stable-and-durable-annualized-bleed-control-for-roctavian-in-largest-phase-3-gene-therapy-study-in-adults-with-severe-hemophilia-a-134-participant-study-met-all-primary-an/</loc>
		<lastmod>2023-01-08T11:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-webcast-on-monday-february-27-at-430-p-m-et-3/</loc>
		<lastmod>2023-02-07T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-virtually-at-svb-securities-global-biopharma-conference-on-february-16-2023/</loc>
		<lastmod>2023-02-14T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-record-fourth-quarter-and-full-year-2022-total-revenues-driven-by-strong-global-demand-for-voxzogo-and-steady-growth-of-enzyme-business/</loc>
		<lastmod>2023-02-27T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-three-investor-conferences-in-march/</loc>
		<lastmod>2023-03-02T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-provides-update-on-fda-review-of-roctavian-valoctocogene-roxaparvovec-gene-therapy-for-adults-with-severe-hemophilia-a/</loc>
		<lastmod>2023-03-06T19:28:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-accepts-biomarins-supplemental-new-drug-application-to-expand-use-of-voxzogo-vosoritide-for-injection-to-treat-children-with-achondroplasia-under-the-age-of-5/</loc>
		<lastmod>2023-03-07T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-share-updated-data-at-2023-american-college-of-medical-genetics-and-genomics-acmg-meeting-demonstrating-commitment-to-understanding-long-term-benefit-of-voxzogo-in-children-with-ac/</loc>
		<lastmod>2023-03-14T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2023-financial-results-conference-call-and-webcast-on-wednesday-april-26-at-430pm-et/</loc>
		<lastmod>2023-04-13T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-record-breaking-first-quarter-2023-results-including-15-year-over-year-growth-of-total-revenues/</loc>
		<lastmod>2023-04-26T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-bank-of-america-2023-health-care-conference/</loc>
		<lastmod>2023-05-04T16:01:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-roctavian-valoctocogene-roxaparvovec-data-from-longest-and-largest-hemophilia-gene-therapy-clinical-trial-program-at-the-international-society-on-thrombosis-and-haemosta/</loc>
		<lastmod>2023-06-22T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/u-s-food-and-drug-administration-approves-biomarins-roctavian-valoctocogene-roxaparvovec-rvox-the-first-and-only-gene-therapy-for-adults-with-severe-hemophilia-a/</loc>
		<lastmod>2023-06-29T14:34:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2023-financial-results-conference-call-and-webcast-on-monday-july-31-at-430pm-et/</loc>
		<lastmod>2023-07-12T09:27:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-strong-second-quarter-2023-results-and-record-breaking-revenues-for-the-first-half-of-2023-including-13-year-over-year-growth-year-to-date/</loc>
		<lastmod>2023-07-31T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-first-person-treated-commercially-with-roctavian-valoctocogene-roxaparvovec-rvox-for-severe-hemophilia-a-in-europe/</loc>
		<lastmod>2023-08-30T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-three-upcoming-investor-conferences-2/</loc>
		<lastmod>2023-09-05T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-pipeline-at-upcoming-rd-day-on-tuesday-september-12th/</loc>
		<lastmod>2023-09-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-innovative-pipeline-at-rd-day-on-september-12th-in-new-york/</loc>
		<lastmod>2023-09-11T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-receives-positive-chmp-opinion-in-europe-to-expand-use-of-voxzogo-vosoritide-to-treat-children-aged-4-months-and-older-with-achondroplasia/</loc>
		<lastmod>2023-09-15T09:29:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-data-showing-long-term-benefit-of-voxzogo-vosoritide-on-growth-in-children-with-achondroplasia-at-2023-european-society-for-paediatric-endocrinology-espe-meeting/</loc>
		<lastmod>2023-09-21T10:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2023-financial-results-conference-call-and-webcast-on-wednesday-november-1-at-430pm-et/</loc>
		<lastmod>2023-10-17T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/u-s-food-and-drug-administration-approves-biomarins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia/</loc>
		<lastmod>2023-10-20T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-retirement-of-jean-jacques-bienaime-appoints-alexander-hardy-president-and-chief-executive-officer/</loc>
		<lastmod>2023-11-01T16:02:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-strong-third-quarter-2023-results-including-continued-profitability-and-15-total-revenue-growth-year-over-year/</loc>
		<lastmod>2023-11-01T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-agreement-with-german-health-insurance-fund-on-reimbursement-amount-for-roctavian-valoctocogene-roxaparvovec-rvox-for-severe-hemophilia-a-in-germany/</loc>
		<lastmod>2023-11-28T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-governance-enhancements-and-value-creation-initiatives/</loc>
		<lastmod>2023-12-20T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-monday-january-8-at-1030-am-pt-130-pm-et-in-san-francisco-ca/</loc>
		<lastmod>2024-01-03T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-roctavian-valoctocogene-roxaparvovec-rvox-data-highlighting-long-term-durability-at-2024-european-association-for-haemophilia-and-allied-disorders-eahad-congress/</loc>
		<lastmod>2024-02-06T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2023-financial-results-conference-call-and-webcast-on-thursday-february-22-2024-at-430pm-et/</loc>
		<lastmod>2024-02-08T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-reports-record-financial-results-for-the-fourth-quarter-and-full-year-2023-and-provides-financial-guidance-for-2024/</loc>
		<lastmod>2024-02-22T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-scheduled-to-participate-in-march-investor-conferences/</loc>
		<lastmod>2024-03-01T09:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-appointment-of-cristin-hubbard-as-chief-commercial-officer/</loc>
		<lastmod>2024-03-07T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/new-data-to-be-presented-for-biomarins-voxzogo-vosoritide-in-children-with-hypochondroplasia-and-achondroplasia-at-the-american-college-of-medical-genetics-and-genomics-acmg-annual-clinica-3/</loc>
		<lastmod>2024-03-12T08:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-first-quarter-2024-financial-results-conference-call-and-webcast-on-wednesday-april-24-2024-at-430pm-et-2-2/</loc>
		<lastmod>2024-04-10T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-reports-record-financial-results-for-the-first-quarter-2024-2-2/</loc>
		<lastmod>2024-04-24T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/new-data-for-biomarins-voxzogo-vosoritide-for-multiple-growth-related-conditions-in-children-presented-at-pediatric-endocrine-society-pes-annual-meeting-3/</loc>
		<lastmod>2024-05-04T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bofa-securities-2024-health-care-conference-on-wednesday-may-15-at-1000am-pt-100pm-et-in-las-vegas-nv-3/</loc>
		<lastmod>2024-05-08T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-new-phase-3-four-year-data-underscoring-long-term-safety-and-efficacy-of-roctavian-valoctocogene-roxaparvovec-rvox-at-international-society-on-thrombosis-and-haemostasis-202-3/</loc>
		<lastmod>2024-06-07T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-data-highlighting-significant-impact-of-voxzogo-vosoritide-in-bone-health-and-health-related-quality-of-life-in-achondroplasia-at-2024-international-conference-on-children-3/</loc>
		<lastmod>2024-06-17T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2024-financial-results-conference-call-and-webcast-on-monday-august-5-2024-at-430pm-et-3/</loc>
		<lastmod>2024-07-23T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/u-s-food-and-drug-administration-approves-biomarins-brineura-cerliponase-alfa-for-children-under-3-years-with-cln2-disease-2-2/</loc>
		<lastmod>2024-07-24T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-updated-strategy-for-roctavian-to-focus-on-u-s-germany-and-italy-2-2/</loc>
		<lastmod>2024-08-05T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-20-y-y-total-revenue-growth-in-the-second-quarter-and-increase-in-full-year-2024-guidance-2-2/</loc>
		<lastmod>2024-08-05T17:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-2024-investor-day-on-september-4th-in-new-york-2-2/</loc>
		<lastmod>2024-08-19T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-new-rd-and-business-development-leadership-2-2/</loc>
		<lastmod>2024-08-21T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-22nd-annual-morgan-stanley-global-healthcare-conference-on-thursday-september-5-at-745-am-pt-1045-am-et-in-new-york-ny-2-2/</loc>
		<lastmod>2024-08-29T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-investor-day-today-at-1030-a-m-eastern-time-2-2/</loc>
		<lastmod>2024-09-04T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-holds-investor-day-provides-new-corporate-strategy-and-introduces-2027-financial-guidance-2-2/</loc>
		<lastmod>2024-09-04T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-data-underscoring-sustained-positive-impact-of-voxzogo-vosoritide-on-health-related-quality-of-life-growth-and-maintenance-of-bone-strength-in-children-with-achondroplasia-2-2/</loc>
		<lastmod>2024-09-18T05:32:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2024-financial-results-conference-call-and-webcast-on-tuesday-october-29-2024-at-430pm-et/</loc>
		<lastmod>2024-10-16T08:30:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-28-y-y-total-revenue-growth-in-the-third-quarter-and-increase-in-full-year-2024-guidance-reaffirms-long-term-guidance-and-outlook/</loc>
		<lastmod>2024-10-29T16:03:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-participate-in-three-upcoming-investor-conferences/</loc>
		<lastmod>2024-11-06T08:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-findings-from-ongoing-studies-of-valoctocogene-roxaparvovec-investigational-gene-therapy-at-the-world-federation-of-hemophilia-2022-world-congress-may-8-11-2022-including-five/</loc>
		<lastmod>2024-11-12T13:37:15+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/european-medicines-agency-validates-biomarins-marketing-authorization-application-for-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a-2/</loc>
		<lastmod>2024-11-12T14:01:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-37th-annual-j-p-morgan-healthcare-conference-in-san-francisco/</loc>
		<lastmod>2024-11-12T14:04:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-promotes-amy-wireman-to-group-vice-president-human-resources/</loc>
		<lastmod>2024-11-12T14:05:16+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-offering-of-450-million-of-0-599-senior-subordinated-convertible-notes-due-2024/</loc>
		<lastmod>2024-11-12T14:14:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2017-financial-results-conference-call-and-webcast-on-wednesday-august-2-at-430pm-et-2/</loc>
		<lastmod>2024-11-12T14:16:55+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-second-quarter-2017-financial-results-conference-call-and-webcast-on-wednesday-august-2-at-430pm-et/</loc>
		<lastmod>2024-11-12T14:22:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/fda-grants-biomarin-orphan-drug-designation-for-naglu-fusion-protein-bmn-250-for-the-treatment-of-mps-iiib-sanfilippo-syndrome-type-b/</loc>
		<lastmod>2024-11-12T14:40:54+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-j-p-morgan-healthcare-conference-2/</loc>
		<lastmod>2024-11-12T14:51:34+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-appoints-william-young-and-kenneth-bate-to-its-board-of-directors/</loc>
		<lastmod>2024-11-12T15:11:21+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-acquires-zystor-therapeutics-inc/</loc>
		<lastmod>2024-11-12T15:14:51+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2010-financial-results/</loc>
		<lastmod>2024-11-12T15:22:43+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-results-for-phase-1-clinical-study-of-bmn-195-for-duchenne-muscular-dystrophy/</loc>
		<lastmod>2024-11-12T15:23:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-reports-encouraging-preliminary-data-on-bmn-110-for-mps-iva/</loc>
		<lastmod>2024-11-12T15:25:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-acquire-lead-therapeutics/</loc>
		<lastmod>2024-11-12T15:25:40+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-bio-ceo-and-investor-conference/</loc>
		<lastmod>2024-11-12T15:27:11+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-j-p-morgan-healthcare-conference/</loc>
		<lastmod>2024-11-12T15:28:02+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-baird-healthcare-conference/</loc>
		<lastmod>2024-11-12T15:41:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/patents-issued-covering-stable-tablet-formulation-and-once-daily-dosing-regimen-for-kuvan/</loc>
		<lastmod>2024-11-12T15:42:32+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-jefferies-healthcare-conference/</loc>
		<lastmod>2024-11-12T15:43:50+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/naglazyme-approved-by-brazils-national-health-surveillance-agency/</loc>
		<lastmod>2024-11-12T15:53:31+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-third-quarter-2008-financial-results-conference-call-and-webcast-on-tuesday-october-28-at-500-p-m-et-2300-cet/</loc>
		<lastmod>2024-11-12T15:59:25+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-citi-biotech-day/</loc>
		<lastmod>2024-11-12T16:00:26+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-citi-small-mid-cap-conference/</loc>
		<lastmod>2024-11-12T16:03:20+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-partner-anges-mg-inc-submits-bla-to-japanese-ministry-of-health/</loc>
		<lastmod>2024-11-12T20:20:24+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-baird-growth-stock-conference-4/</loc>
		<lastmod>2024-11-12T20:21:17+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-results-from-phase-2-clinical-study-of-6r-bh4-in-poorly-controlled-hypertension/</loc>
		<lastmod>2024-11-12T20:22:49+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-marketing-approval-for-aldurazyme-in-japan/</loc>
		<lastmod>2024-11-12T20:25:44+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-alliant-pharmaceuticals-announce-north-american-licensing-agreement-for-orapred/</loc>
		<lastmod>2024-11-12T20:27:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-sg-cowen-co-6th-annual-global-health-care-conference/</loc>
		<lastmod>2024-11-12T20:28:57+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-second-quarter-2005-financial-results/</loc>
		<lastmod>2024-11-12T20:30:22+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-appointment-of-stephen-aselage-as-senior-vice-president-of-global-commercial-operations/</loc>
		<lastmod>2024-11-12T20:31:58+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-and-orbimed-settle-proxy-contest/</loc>
		<lastmod>2024-11-12T20:32:59+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-issues-revised-financial-guidance-for-2004/</loc>
		<lastmod>2024-11-12T20:35:05+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-voxzogo-vosoritide-in-children-with-achondroplasia-at-the-european-society-for-paediatric-endocrinology-espe-m/</loc>
		<lastmod>2024-11-16T10:45:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-legal-action-against-ascendis-pharma-a-s-in-european-unified-patent-court/</loc>
		<lastmod>2025-01-13T12:00:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference-on-monday-january-13-at-900-am-pt-1200-pm-et-in-san-francisco-ca/</loc>
		<lastmod>2025-01-13T17:21:04+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-reports-fourth-quarter-and-full-year-2024-results-sets-full-year-2025-guidance/</loc>
		<lastmod>2025-02-19T21:41:14+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-and-webcast-on-wednesday-february-19-2025-at-430pm-et/</loc>
		<lastmod>2025-02-24T10:44:07+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-announces-appointment-of-timothy-p-walbert-to-board-of-directors/</loc>
		<lastmod>2025-02-24T16:05:00+00:00</lastmod>
	</url>
	<url>
		<loc>https://www.biomarin.com/news/press-releases/biomarin-to-present-at-the-td-cowen-45th-annual-healthcare-conference-on-tuesday-march-4-at-650-am-pt-950-am-et-in-boston-ma/</loc>
		<lastmod>2025-02-25T14:04:03+00:00</lastmod>
	</url>
</urlset>
<!-- XML Sitemap generated by Yoast SEO -->